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Since miRNAs discovery, evidence keeps accumulating on their role in human 
physiology for homeostasis and implications during disease development. Upon the 
discovery that miRNAs could be encapsulated in exosomes and provide protection, 
evidence keeps accumulating on the possibility for miRNAs to be transferred between 
distant cells and elicit gene expression changes, and clinical trials are being developed to 
identify miRNAs in body fluids that could predict disease outcomes based on miRNA 
encapsulation in exosomes making them stable in body fluids. Recently, studies have 
shown that dietary miRNAs encapsulated in exosomes can be absorbed in mice and 
humans, and on the other hand, milk consumption has been associated with lower uric 
acid concentrations and distinct benefits for human health, therefore the aims of this work 
were to determine whether milk exosome and RNA-depleted (ERD) and exosome and 
RNA-sufficient (ERS) diets could alter the concentrations of purine metabolites in mouse 
livers, and to determine whether diets depleted of bovine milk alter the plasma 
concentration and urine excretion of purine metabolites in adults and infants, 
respectively. Effects upon ERD diet were observed, hepatic purine metabolites in ERD 
	  
fed mice were significantly higher compared to ERD controls. Additionally, plasma 
concentrations and urine excretion of purine metabolites were significantly higher in 
dairy avoiders and in infants fed soy milk, and finally purine hepatic gene expression in 
mice was significantly different between ERD and ERS. Comprehensively, diets depleted 
of bovine milk exosomes and RNA cargos caused increases in hepatic purine metabolites 
in mice, and in plasma and urine from adults and infants compared to exosome-sufficient 
controls. These findings are important since purines play a role in intermediary 
metabolism and cell signaling, therefore there is a possible link between milk benefits 
and dietary exosomes and their miRNA cargo transfer. Further research will need to 
address the underlying mechanisms that drive the purine concentration and enzyme gene 
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miRNAs are endogenous short (22 nt) non-protein coding RNA sequences with a hairpin 
stem shape, that serve as post-transcriptional gene expression regulators. The synthesis of 
miRNAs is a coordinated process where firstly, miRNAs are transcribed from introns or 
exons by Pol II enzyme, and some miRNAs can share promoters with other messages, 
however most miRNAs genes are distant from protein-coding genes. Interestingly, 
several miRNAs are highly conserved between species and they are organized as poly-
cistronic units. miRNAs are subsequently trimmed by Drosha (along with DGCR and 
RNase III endonuclease protein activity), which cleaves the transcribed pri-miRNA 
sequence, resulting in the liberation of a ~60-70 nt doubled-stranded hairpin named pre-
miRNA, which maintains a 3´overhang nt. Exportin 5 with Ran-GTP activity 
subsequently transports the pre-miRNA to the cytoplasm. Once the pre-miR is in the 
cytosol, Dicer along with RNase III activity, cleaves the pre-miRNA ~22 nt from the end 
of the sequence by recognizing the double stranded part of the pre-miRNA, mainly based 
on the protein harboring affinity for the 5´phsophate and 3´ nt overhang of the stem loop 
base. This will result in an 11nt sequence mature miRNA (1–5).   
To proceed with repressive activity, Dicer guides the miRNA into an Argonaute2 (Ago2) 
protein forming the RNA-induced silencing complex (RISC), which selects 1 strand form 
the miRNA:miRNA duplex to achieve mRNA repression, liberating the other miRNA 
strand for subsequent degradation. RISC will recognize mRNAs based on perfect or 
nearly perfect paring with the miRNA sequence form the RISC. The miRNA maintains a 
base pairing with the 3´UTR of the mRNA, with either a perfect match or near perfect 
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pairing, the latter being more common. The requirements for pairing are mostly, for the 
miRNA 5´region (seen sequence) to bind at the 3´UTR of the message resulting in the 
formation of the mRNA:miRNA duplex (Figure1-2) (1–7). 
 
Figure 1. miRNAs biogenesis and function. Drosha, Exportin-5 and 
Dicer accordingly acting towards miRNA maturation (Adapted 
from O´Kelly, 2012).  
 
Figure 2. miRNA and mRNA complementarity. Duplex formation 
involves matching of the mRNA and miRNA seed region sequence 
(Adapted from Bartel, 2009). 
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Depending on the degree of complementarity, the message will be either cleaved or 
translation halted, since ribosomes will be blocked to perform their function. Hence, 
miRNAs activity will in most cases result in a decrease of the protein output (1–7).  
miRNAs expression occurs in most tissues, it is finely tuned and for some miRNAs, their 
expression is constrained to only one tissue or certain stage of the life cycle, providing 
them with an spatiotemporal expression pattern that results in an specific miRNA milieu 
providing a context for all cells to maintain homeostasis (1–3) Therefore, miRNAs are 
indispensable mediators for mostly all physiological processes throughout life cycle, 
including developmental processes, cell differentiation and cell cycle arrest, and their 
expression is modified upon situations such as nutrient deprivation, hypoxic environment, 
among many others (1–3) Importantly, it has been established that more than 60% of 
human protein coding genes are conserved targets for miRNAs, and 1-2% of predicted 
protein coding human genes correspond to miRNAs expression (1,6,8). 
 
miRNAs can target many messages and mRNAs can be targeted by many miRNAs, this 
represents high complexity for effectively investigating possible miRNA:mRNA 
interactions and the phenotypic consequences of these interactions, hence computational 
and systems biology approaches are currently being developed and tuned to predict 
interactions and keep advancing in the research field. The basis of most prediction 
algorithms involve evolutionary conservation, based on mRNA 3´UTR being highly 
conserved among species due to selective pressure, and phenotypic analyses include 
network construction to identify possible disrupted hubs in response to specific 
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miRNA:mRNA interactions (1,6,8–10). For instance, Boudreau et al. performed a 
transcriptome-wide discovery of miRNAs binding sites in brain, since miRNAs hold 
essential roles in neurological functions such as synaptic plasticity, and slight miRNAs 
disturbances result in repercussions in brain physiology. The study found by HITS-CLIP 
(High throughput sequencing – cross linking immunoprecipitation), an enriched 
interaction between miR-128 and MAPT gene, which encodes for TAU proteins involved 
in Alzheimer´s disease (11), suggesting that the loss-of-function of these miRNA could 
be implicated in the development of the neurological disease.  
In addition, throughout human development, certain miRNA species are fundamental for 
processes like osteoblast differentiation, and studies have shown that miR-29b directly 
down regulates osteoblast inhibitors providing an spatiotemporal control of development 
and homeostasis during osteogenesis by miRNAs (12).  
 
miRNAs have been subject of research for numerous diseases with the attempt of 
determining miRNA profiles that could be involved in the development of the disease to 
develop miRNA therapies or profiles that result from the disease to detect biomarkers, 
preventing advance of disease. Numerous clinical trials are currently researching 
miRNAs. During cancer progression, characteristic tumor pathways can be controlled by 
single or multiple miRNAs, commonly engaging reciprocal feedback interactions with 
mRNA targets, some miRNAs acting as tumor suppressors while others act as oncomiRs. 
Cancer cells actually develop mechanisms to dysregulate miRNA expression including 
the generation of mRNA isoforms with shortened 3 ´UTR (13,14). Examples include 
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miR-200c inhibiting ZEB transcription factor which promotes EMT (15,16), general 
lower expression of miRNAs during hepatocellular carcinoma (17), the interplay between 
miRNAs and the development of the Warburg metabolic phenotype inducing a tumor 
promoting microenvironment (18),  consistent up regulation of miR-21 in different types 
of cancers resulting in tumorigenesis (19), a 4-miRNA signature displayed during non-
small-cell lung cancer (20), the p53-miR34 regulatory axis that harbors tumor 
suppressive activity (21), or in contrast, miR-155 which repress p53 activity resulting in 
tumor progression (22), among many others. In sum, cancer progression is deeply 
regulated by miRNAs.  
Other diseases where miRNAs are players in the pathogenesis include autoimmune 
diseases, infections, metabolic conditions and vascular/cardiac illnesses (23–25). 
Currently, miRNAs have inherent therapeutic applications during endothelium 
dysfunction, for instance miR-30 family contribute in the protection against atherogenesis 
(24) and during diabetes, studies have shown that miR-375 and -144 disrupt insulin 
sensitivity during hyperglycemia (25). 
Interestingly, Fabbri et al have shown a non-canonical mechanism were miRNAs 
encapsulated in exosomes can be transferred from cell-to-cell. Exosome encapsulated 
miR-21 and mir-29 can bind to Toll-like receptors in immune cells, leading to TLRs 
promotion of prometastatic inflammatory response, meaning that miRNAs can bind to 




Exosomes are cell-derived nanovesicles (40-100 nm) released by all cells, serving as 
strong cell-to-cell communicators. Exosomes emerge during the development of late 
endosomes to become MVBs, where the endosome membrane is inviginated, forming 
intra luminal vesicles, resulting in the completed process of creating MVBs, which 
contain the intraluminal vesicles, namely exosomes. The process involves the 
accumulation of ubiquitinated proteins, which are transferred by the cytosolic endosomal-
sorting complex required for transport (ESCRT). There are 4 different types of ESCRT 
involved in the formation of exosomes, ESCRT-0 sequesters ubiquitinated proteins, 
ESCRT-I coordinated with ESCRT-II start the budding of the endosomal membrane, and 
finally ESCRT-III is involved in the release of intraluminal vesicles to become exosomes 
(Figure 3) (27–33).  
 
Figure 3. Exosomes assembly and release. Machinery for exosomes assembly involves 
ESCRT interaction with endosomes (Adapted from Cocucci, 2015). 
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During exosomes assembly, one of the most important encapsulated cargo correspond to 
miRNAs, since their transport influences numerous physiological and pathological 
functions, and interestingly there is a curvature sorting for miRNA content during 
budding of the membrane, this confers control for the physiological role the exosome will 
play (27,30,32).  
Exosomes are composed by a lipid bilayer and their uptake by target cells is mediated 
usually by endocytosis or phagocytosis, implicating an specific exosome membrane 
glycosylation pattern to be interacting with the recipient cell membrane (27,30,33). 
Exosomes miRNA cargos are released within the recipient cell, leading to post-
transcriptional gene regulation, hence exosomes can modify the physiological state of the 
recipient cell (28–30). Controlled miRNA encapsulation is relevant since all studied 
mRNA:miRNA interactions are influenced by cell communication since the exosomes 
lipid bilayer confer protection for miRNA transport across tissues against RNases and 
low-pH (30). 
Furthermore, based on the possibility of transporting miRNA and other cargoes, 
exosomes are widely studied in the development of various diseases, for instance in 
cancer, tumors secrete exosomes contributing to metastasis by transferring miRNA 
species that favor tumorigenesis and studies have shown that cancer exosomes harbor 
miRNA biogenesis machinery, and exosomes are implicated in the tumor-genetic 
alterations within the tumor microenvironment (31,33–36).  
Moreover, during inflammation exosomes can transport miR-155 which enhances 
inflammatory activity (37), while during type 2 diabetes, specific miRNA profiles have 
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been found in exosomes, and during obesity, exosomes originated form adipose tissue 
can increase cytokine secretion and impair insulin signaling (32). Finally as miRNAs 
contained in exosomes have been found to regulate TLRs activity (26), Paschon et al 
described exosomes secreted by neuronal cells, activate TLRs resulting in inflammation 
that contributes to the development of brain disorders including Alzheimer’s, Parkinson’s 
disease and amyotrophic lateral sclerosis (38). Notably, since exosomes are present in 
many body fluids including urine, plasma and breast milk, exosomes can serve as 
accurate biomarkers for disease (27,39,40) . 
 
Remarkably, based on exosome encapsulation, plant miRNAs are present in animal body 
fluids (41,42), Zhang et al. was the first to demonstrate a possible cross-kingdom gene 
regulation describing that miR168a abundant in rice and one of the most enriched 
exogenous miRNA in Chinese population sera, can cross the gastro-intestinal (GI) track 
and bind to low density lipoprotein receptor adaptor 1 (LDLRAP1) mRNA, inhibiting 
their expression in mice liver, resulting in a decrease of LDL removal from plasma (41).  
Moreover, exosomes allow for plant miRNAs to be stable in cooked foods and to resist 
low-pH and RNases activity in the GI track (41–44). 
Dietary exogenous exosomal miRNAs are also present in animal sources such as pork, 
beef and chicken (45) and studies have shown that humans absorb egg-borne miRNAs, 
who are delivered to PBMCs where they affect gene expression (46). 
In human breast milk, numerous studies have shown the presence of miRNAs, mainly 
encapsulated in exosomes. These miRNAs have been implicated in immunoprotective 
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activities, growth and development, transcriptional regulation, metabolic response, cell 
proliferation and apoptosis, lung epithelial progenitor cell differentiation, and epithelial-
to-mesenchymal transition, providing a new insight of how breast milk modulate infant 
growth and development (47–51). Interestingly, certain plant miRNA species have been 
identified in human breast milk exosomes (52,53). Several studies have described that 
encapsulation in exosomes allow for human milk miRNAs to resist harsh conditions 
through the intestinal barrier and exert effects in infant development and maturation (54).  
 
Naturally, numerous miRNAs have also been identified in cow´s milk, mainly 
encapsulated in exosomes resulting in miRNA stability during milk processing and GI 
transport conditions, for instance temperature changes, low-pH and RNases activity (55–
59).  Studies in our laboratory have displayed that humans and mice can absorb cow´s 
milk miRNAs and the absorbed miRNAs are able to alter gene expression. More 
importantly, endogenous miRNA synthesis cannot compensate for the depletion of 
dietary miRNAs (60). Bovine milk exosomes are transported across the intestine by 
glycoprotein dependent endocytosis in Colon Carcinoma Caco-2 Cells and Rat Small 
Intestinal IEC-6 cells. Also, endocytosis transport is observed across endothelium in 
Human Vascular Endothelial (HUVEC) cells. Additionally, fluorophore-tagged milk 
exosomes can accumulate in liver spleen and brain after oral administration, 
demonstrating the host can absorb exosomes and their miRNAs. Finally, exosomal 
miRNAs can be uptaken by human macrophages, and for instance in mice, absorbed 
exosomes can exert immunoregulatory effects (55,59,61–64).  
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Currently, 417 distinct miRNAs have been detected in bovine milk exosomes (65), which 
could interact with host mRNA targets. Furthermore, oral delivery of bovine milk 
exosomes displayed osteocytes increase in mice (66), while in C2C12 myotubes, increases 
in skeletal muscle protein synthesis and anabolism was observed upon whey protein 
derived exosomes treatment, possibly lead by exosomal miRNAs (67).  
 Moreover, In silico predictions have identified numerous exogenous miRNAs 
encapsulated in exosomes as transportable candidates in human circulation that harbor 
identical sequences with humans, providing them the possibility of targeting mRNAs 
regulating gene expression (68),  based on this plethora of dietary miRNAs from diverse 
food sources that could have diverse mRNA targets, a dietary microRNA Database 
(DMD) was developed and is currently available for public use (69).  
Altogether, these observations lead to conclude that milk-derived exogenous miRNAs 
can be qualified as novel nutrient components and could be relevant for the pathogenesis 
of certain diseases (41,42,60,66,67,70). This statement challenges the paradigm that 
miRNAs can have physiological effects only when synthetized endogenously, since 
exosomes and their RNA cargos may also be obtained from dietary sources such as 
bovine milk.  
 
Importantly, human breast milk is the optimum nutritional source for infants, and 
compared to commercial formulas, human breast milk provides superior benefits related 
to adequate growth, cognitive development, insulin sensitivity, immunological function, 
antioxidant activities, bone mineral content, and lower risk biomarkers for future obesity 
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during the first months of life. In addition, a different metabolite profile was detected by 
serum biochemistry in infants and gene expression in breast milk cells can impact 
infant´s development (71–77). 
Moreover, bovine milk and dairy products are globally consumed foods by children and 
adults. Notably, epidemiological studies have established a negative association between 
milk intake and development of type 2 diabetes, hypertension and cardiovascular disease, 
metabolic syndrome and a positive correlation between milk intake and cognitive 
function, particularly memory improvement (78,79) Interestingly, supporting evidence 
has demonstrated that milk consumption can decrease serum uric acid concentrations 
(80).  
 
Uric acid is a purine metabolite, the metabolism of purines involve 2 biosynthetic and 
one catabolic pathways, purine de novo and salvage synthesis is mediated by numerous 
signals and various critic transcription factors, including mTOR, Myc, p53, among others 
and it also involves a purinosome assembly (81,82). Additionally it is known that purines 
are also regulated by the hepatic circadian rhythm (83).  Purines participate in numerous 
critical cellular functions and biological processes thus they must be quantitatively 
controlled during quiescent or proliferative cell conditions (84). Defects in purine 
metabolism can result in disease development in infants and adults (85).  
It is known that purine continuous and persistent increased concentrations can lead to the 
aberrant activation of signaling molecules involved in pathogenic cascades, and 
alterations in the purine metabolic pathway can lead to the development of several 
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diseases. For instance during cancer, purines can serve as signaling molecules involved in 
cancer progression, as such certain adenosine receptors activation leads to 
immunosuppressive mechanisms that drive to tumor growth (86–88), and  it is known 
that adenosine is a signaling molecule in angiogenesis and in some cell conditions,  
increased adenosine results in p53 activation (89,90). 
Moreover, implications of deregulated purine metabolism and purinergic signaling have 
been associated to neurological function, cardiovascular health, metabolic syndrome, 
non-alcoholic fatty liver disease, type 2 diabetes, chronic renal disease and fertility 
impairment (91,92). Particularly, high concentrations of UA have been associated with 
the development of diabetes, metabolic syndrome, and cancer (93–96). 
Additionally, studies determined that ATP and adenosine impairs hippocampal synaptic 
plasticity, thus learning and memory process (97,98). Furthermore, a differential pattern 
of purine expression was detected in the precuneus of Alzheimer’s patients, with an 
increased expression of AK1 and NT5C and decreased expression of AK4 and NME6 
(99). Finally, cognitive impairment during aging, including deficits in learning and 
memory, is led by a metabolic drift characterized by altered purine biosynthesis and 
degradation (100). 
A metabolomic and transcriptomic approach to identify a differential phenotype in 
response to bovine milk exosome and their RNAs depletion could help confirm miRNA 
transfer among different species through diet and identify functional consequences, such 
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Background: Humans and mice absorb bovine milk exosomes and their RNA cargos.  
Objectives: Objectives were to determine whether milk exosome and RNA-depleted 
(ERD) and exosome and RNA-sufficient (ERS) diets alter the concentrations of purine 
metabolites in mouse livers, and to determine whether diets depleted of bovine milk alter 
the plasma concentration and urine excretion of purine metabolites in adults and infants, 
respectively.  
Methods: C57BL/6 mice were fed ERD (providing 2% of the microRNA 
cargos compared to ERS) and ERS diets starting at age 3 weeks; livers were 
collected at age 7 weeks. Plasma and 24-h urine samples were collected from 
healthy adults who consumed (DC) or avoided (DA) dairy products. Spot urine 
samples were collected from healthy infants fed human milk (HM), milk 
formula (MF) or soy formula (SF) at age 3 months. Purine metabolites were 
analyzed in livers, plasma and urines; mRNAs and microRNAs were analyzed 
in female mice livers. 
Results: Nine hepatic purine metabolites in ERD fed mice were 1.76 ± 0.43 times the 
concentrations in ERS (P < 0.05). Plasma concentrations and urine excretion of purine 
metabolites in DA was up to 1.62 ± 0.45 times the concentrations in DC (P < 0.05). The 
excretion of 13 purine metabolites in urine from SF infants was up to 175 ± 39 times the 
excretion in HM and MF (P < 0.05). mRNA expression of 5’-Nucleotidase, Cytosolic 
IIIB and adenosine deaminase in mice fed ERD was 0.64 ± 0.52 and 0.60 ± 0.28 times 




Conclusion: Diets depleted of bovine milk exosomes and RNA cargos caused increases 
in hepatic purine metabolites in mice, and in plasma and urine from adults and infants 
compared to exosome-sufficient controls. Findings are important, because purines play a 
role in intermediary metabolism and cell signaling. 




Virtually every living cell produces and secretes a class of nanoparticles named exosomes 
(1, 2). Exosomes deliver cargos such as lipids, proteins and various species of RNA to 
adjacent or distant recipient cells. Exosome uptake by recipient cells is mediated by 
endocytosis (3). The delivery of exosome cargos elicits changes in gene expression and 
metabolism in recipient cells (1, 2). Among exosome cargos, microRNAs are of 
particular interest, because more than 60% of human genes have conserved microRNA-
binding sites and loss of microRNA maturation is embryonic lethal (4, 5). MicroRNAs 
have been implicated in most physiological and pathological conditions (6, 7). 
We have provided strong evidence that exosomes and their RNA cargos do not 
originate exclusively in endogenous synthesis, but may also be obtained from dietary 
sources such as bovine milk. The following lines of evidence were presented in support 
of this paradigm-shifting theory. First, the plasma concentrations of milk-borne 
microRNAs increased following a milk meal in humans, whereas the concentration of a 
microRNA not detectable in milk (miR-1) did not increase (8, 9). Recently, we confirmed 
these findings by using a nucleotide-specific PCR protocol, RNase H2 PCR, which 
distinguishes microRNAs derived from endogenous synthesis and those obtained from 
bovine milk (10). Second, human and rodent intestinal cells, human immune cells and 
human vascular endothelial cells accumulate bovine milk exosomes by endocytosis and 
secrete microRNA across the basolateral membrane (11-13). These observations are 
consistent with reports suggesting that orally administered milk exosomes accumulate in 
peripheral tissues and that only about half of the extracellular RNAs in human plasma are 
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of human origin (14, 15). Third, in vitro evidence suggests that microRNAs are protected 
against degradation by RNases and low pH through encapsulation in exosomes, and 
partially protected against degradation in the TNO intestinal model (16, 17). Some voices 
of concern remain, doubting that the absorption of dietary microRNAs is quantitatively 
meaningful (reviewed in (18) and discussed below). However, evidence is accumulating 
that RNAs from dietary sources other than milk are also bioavailable (reviewed in (18); 
additional recent evidence in (19)). 
Of note, when mice were fed an AIN-93G-based diet, modified to be defined by its 
content of bovine milk exosomes for four weeks, plasma microRNA levels were ≈60% 
lower in mice fed exosome RNA-depleted (ERD) diet compared to mice fed the exosome 
RNA-sufficient (ERS) diet (8). The observation that endogenous microRNA synthesis 
cannot compensate for dietary depletion raises the important question as to what the 
phenotypes of dietary RNA depletion might be. Our first attempts at identifying 
phenotypes of milk RNA depletion included an unbiased liver metabolomics screen of 
mice fed ERD and ERS diets, which suggested that hepatic adenosine and inosine were 
among the metabolites for which the concentrations were higher in ERD mice than in 
ERS mice. Here, we followed up on this initial observation and conducted a series of 
studies, specifically targeting purine metabolites with the following objectives. 1) 
Conduct a comprehensive analysis of hepatic purine metabolites in mice fed ERD and 
ERS diets. 2) Assess the effects of ERD and ERS diets on the expression of enzymes in 
purine metabolism in murine livers. 3) Assess the effects of milk intake on purine 
metabolites in human adults and infants. This study is significant since it provides a new 
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insight into hepatic purine metabolism pathways impacted by dietary milk-derived 
microRNA in mice and shows, for the first time, marked purine metabolic shifts also take 
place in infants fed milk-free formula. Purines play a role in numerous pathways in 
energy metabolism and cell signaling (20). 
 
2. Materials and methods 
2. 1 Mouse feeding studies 
C57BL/6 mice (Jackson Laboratories), age 3 weeks were randomly assigned to two diet 
groups at weaning (21), housed in groups, 12:12 light cycle and at ~22°C. Absence of sex 
effects on liver metabolites was demonstrated by referencing against 5 male C57BL/6 
mice determined hydrophilic-interaction chromatography-multiple reaction monitoring-
tandem mass spectrometry (HILIC-MRM-MS/MS, Supplemental Table 1). Diets were 
based on the AIN-93G formula, and modified by their content of exosomes and their 
RNA cargos from bovine milk (8, 22). One group was fed a milk exosome and RNA-
depleted (ERD) diet, whereas the other group was fed a milk exosome and RNA-
sufficient (ERS) diet, both for 4 weeks. Briefly, ERD and ERS diets are based on the 
AIN-93G formulation (8, 22). In the diets, lyophilized milk powder (and soy protein) 
substitutes for milk casein in the AIN-93G formulation to eliminate dairy exosomes 
present in the AIN-93G formulation. The milk added to the diets provides the equivalent 
of 0.5 L milk consumed by a human adult per day, adjusted by body weight in mice. The 
milk used to prepare the powder for the ERD diet is ultrasonicated for 1.5 h and 
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incubated for 1 h at 37°C prior to lyophilization; the milk used to prepare the powder for 
the ERS is not ultrasonicated.  
Ultrasonication leads to a transient disruption of exosome membranes and a >98% 
depletion of RNA cargos in exosomes, 20% decrease in exosome count 
(9.1x1012±7.1x1011 exosomes/mL in ERS milk vs. 7.3x1012±3.5x1011 exosomes/L in 
ERD milk; P < 0.05, n = 3) and >60% decrease in intestinal exosome transport rates (23). 
Diet ingredients other than milk are not ultrasonicated, i.e., nutrients other than exosomes 
and their RNA cargos, including purines are the same in either sonicated milk or non-
sonicated milk, used for ERD and ERS diets accordingly (see below). Differential purine 
content from the two diets was tested by HPLC, three samples were analyzed, using 
separate batches of both ERD and ERS milk. Mice had free access to diets and water for 
the entire study period, but no differences in food and water intake were noted in the two 
groups (not shown). At age 7 weeks, mice were euthanized using carbon dioxide during 
postabsorption and livers were flash frozen in liquid nitrogen and immediately stored at -
80°C until analysis. Body composition was assessed by dual-energy X-ray 
absorptiometry at time of study termination prior to liver extraction. Studies were 
approved by the University of Nebraska-Lincoln Institutional Animal Care and Use 
Committee (protocol 1229). 
 
2.2 Human feeding studies 
Cross-sectional studies were conducted in infants and adults. Spot urine samples were 
collected from infants fed human milk (HM, n = 45), milk formula (MF, n = 41) or soy 
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formula (SF, n = 46) at age 3 months. The key to group assignments was broken after 
purine and creatinine analyses were complete. The infant population and formulas fed 
have been described elsewhere ((24). The Beginnings Study, Clinical Trial # 
NCT00616395). In addition, two cohorts of apparently healthy adults were recruited 
(Supplemental Table 2). Dairy consumers (DC) were persons who regularly consume a 
self-chosen diet providing at least 0.50 L milk per day and perhaps other dairy, whereas 
dairy avoiders (DA) were persons who regularly consume diets free of animal milk and 
less than two weekly servings of dairy (1 serving = 0.25 L) other than milk. Dairy 
consumption was assessed by questionnaire. DA were instructed to avoid dairy other than 
milk altogether for at least two weeks before sample collection. Exclusion criteria shared 
by both groups included history of metabolic disease including lactose intolerance, body 
weight of less than 55 kg, history of intestinal surgery, smoking and use of prescription 
and over-the-counter medications less than four weeks before sample collection. Blood 
samples and 24-h urine samples were collected after an overnight fast. EDTA tubes were 
used to avoid inhibition of PCR reactions (10). Plasma was collected by centrifugation 
and stored at -80ºC until analysis. Urine samples were briefly centrifuged to remove 
debris and stored at -80ºC until analysis. Studies were approved by the Institutional 
Review Board at the University of Nebraska-Lincoln (protocol NU ID 14778). We 
estimated the power of human studies to detect changes in purine metabolism based on 
the differential concentration of seven purine metabolites between ERD and ERS diets, 
including adenosine, guanosine, inosine, xanthine, adenine and hypoxanthine. Fourteen 
infants allow to detect a 40% change in urinary purine metabolites, and six adults allow 
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to detect a 60% change of purine metabolites in urine and plasma at 1-β = 0.8 and α = 
0.05. For both human cohorts, there were no apparent sex effects on purine metabolism. 
 
2.3 Analyses of purine metabolites 
Mouse livers polar and non-polar metabolites were extracted with a mixture of 
chloroform, methanol and water and analyzed by liquid chromatography-mass 
spectrometry as described previously (25) for non-targeted metabolomics. Metabolites 
were identified using the METLIN database (26). Multivariate analyses were performed 
using Metaboanalyst 3.0 (27). Mouse livers and human plasma and urine metabolites 
were extracted using methanol, dried, and stored at -80°C until analyzed as previously 
described (28), only differing by the use of a 5-µm Luna NH2 column (150 x 2 mm) at a 
flow rate of 0.4 mL/min. Prior to mass spectrometry, samples were re-suspended in 40 
µL of 85% acetonitrile and 20 µL were injected. Targeted metabolite quantification was 
performed using a QTRAP 6500 mass spectrometer (AB Sciex LLC) coupled to a 
Shimadzu Nexera X2 HPLC system (Shimadzu Co., Japan). Peak analysis was performed 
using Analyst Software (AB Sciex LLC). Multiple reaction monitoring transition data 
were collected for each purine metabolite (28). Select purines in livers, plasma and urine 
samples in the different diets were also analyzed by HPLC (inosine and hypoxanthine) as 
described previously with minor modifications (29), the Amplex® Red Xanthine Assay 
Kit (Life Technologies) and the BioVision Uric Acid Colorimetric/Fluorometric Assay 
Kit (Biovision Inc.) following the manufacturer´s instructions. The concentrations of 
purine metabolites in urine were normalized using creatinine, which was measured by 
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using a colorimetric assay (30). Adult urine uric acid test was measured in samples 
collected in a 24-h period, whereas purines from infant were analyzed in spot urine 
samples which require normalization by creatinine. 
 
2.4 RNA sequencing analysis 
Total RNA and microRNAs were extracted from mouse livers using spin columns 
(Qiagen, Inc.) and shipped to BGI, Inc. (Hong Kong, China) for sequencing using the 
Illumina HiSeq 2500 platform with protocols of 125-bp read length, paired end and 50-bp 
read length, single end, respectively. Data quality control was performed using FastQC 
(31). For RNA, adaptor sequences and reads containing ambiguous bases or having 
average quality score less than 30 were removed. The remaining high-quality reads were 
aligned to the reference sequences in murine RNA [GRCm38, mm10] by using RSEM 
(32) and Tophat (33). Cufflinks and Cuffdiff was used to obtain the transcripts and 
quantify according to the sum of normalized reads units displayed as Fragments Per 
Kilobase Million (FPKM) (34).  DESeq2 R was used to determine differentially 
expressed genes, based mainly on fold change, p value and q-value (FDR, False 
Discovery Rate) (35). For microRNA, expression was quantified using CAP-miSeq, and 
miRBase (Version 21) was used as reference library for annotation (36, 37). We have 
carefully filtered out the low-quality reads and strictly mapped the qualified reads to all 
known mature sequence, precursor sequences and genomes of mouse. Raw sequence data 
were deposited in the NCBI-BioProject database under accession No. PRJNA428903 for 
RNA-Seq data and PRJNA428904 for microRNA-Seq data. 
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Spin columns for RNA purification may be contaminated with microbial RNAs and 
produce false positive results in microRNA analysis (38). We confirmed hepatic 
microRNA-Seq data by real-time quantitative PCR (RT-qPCR), using microRNAs 
isolated using spin columns that were purified by treatment with 0.5% sodium 
hypochlorite (38). We selected three microRNAs that represented the top (miR-340-5p), 
middle (miR-99b-5p) and bottom (miR-362-3p) tertile of microRNA abundance in 
microRNA-Seq analysis. In addition, miR-340-5p has a nucleotide sequence 
complementary to mRNAs implicated in purine metabolism. mRNA-microRNA 
interactions were predicted by using miRWalk (39).   
 
2.5 Statistical analysis 
Multivariate statistical analysis, pathway enrichment analysis, and topology analysis 
approaches were used in order to compare high-throughput data between ERD and ERS 
using Metaboanalyst 3.0 (27). Homogeneity of variances was confirmed by using F-test.  
Kolmogorov-Smirnov test was used to confirm normal distribution. Differences between 
two groups were determined by unpaired t-test. If variances were heterogeneous, we used 
Welch´s test for pairwise comparisons. One-way ANOVA and Tukey´s posthoc test was 
used for comparisons among more than two groups. Homogeneity of variances was 
confirmed using Barlett’s test. Effects of diets were considered statistically significant if 
p < 0.05. Data in figures and tables are reported as mean ± SEM and mean ± SD, 




3. Results  
3.1 ERD and ERS milk contained feeding in mice 
ERD and ERS diets contained the same concentrations of the purine metabolites 
hypoxanthine and inosine (Supplemental Table 3). Physical activity, food consumption, 
feeding frequency, water consumption and respiratory exchange rate was the same in 
mice fed ERD or ERS diets (23). Body weight, lean body weight and fat mass were the 
same in the two diet groups at age 7 weeks (Supplemental Figure 1). 
 
3.2 Hepatic purine metabolites 
When the metabolome in mouse livers was analyzed using non-targeted mass 
spectrometry, seven purine metabolites were among the 25 metabolites (purines and non-
purines) affected the most by ERD or ERS diets (Figure 1A). In principal component 
analysis, mouse livers were clustered separately by dietary treatment (Figure 1B), which 
was primarily driven by differential abundance of purine metabolites. When non-targeted 
metabolite analysis was followed up with a targeted analysis of purine metabolites by 
LC-MS, the concentrations of nine measured hepatic purine metabolites were 
significantly higher in ERD mice compared to ERS mice (Figure 1C). Metabolite set 
enrichment analysis of hepatic metabolites suggested that purine metabolism was among 
the pathways most affected by ERD diet in mice (Supplemental Figure 2). When 
individual purines were analyzed by using colorimetric assays, HPLC and HILIC-MRM-
MS/MS, the hepatic concentrations of xanthine and guanosine triphosphate were 
significantly higher in mice fed ERD than in mice fed ERS (Supplemental Figure 3), 
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whereas the concentrations of seven other purine metabolites in ERD mice were not 
significantly different from ERS mice (0.07 < P < 0.46). 
 
3.3 Liver transcriptomics 
Two hundred seventy-two mRNAs were differentially expressed, with criteria of at least 
1.5-fold difference, a p-value less than 0.05 and a q-value less than 0.05 (|log2FC| ≥ 0.8, 
P < 0.05, Q < 0.05), in livers from mice fed ERD or ERS diets (Figure 2A). The mRNAs 
that were differentially expressed included adenylate kinase 1 and cAMP-specific 3', 5’-
cyclic phosphodiesterase 4D, which were 6,216% and 175% more abundant, respectively, 
in ERD than in ERS. The unbiased RNA-seq analysis was supplemented with a targeted 
in-depth analysis of mRNA, which detected 9 enzymes in purine metabolism for which 
the expression of mRNA was significantly different between mice fed ERD and ERS 
diets (Table 1). Forty-nine microRNAs were expressed at a lower level in livers from 
mice fed the ERD diet compared to mice fed the ERS diet (|log2FC| ≥ 1.0, P < 0.05) 
(Figure 2B). Five of these differentially expressed microRNAs (miR-338-5p, miR-340-
5p, miR-17-5p, miR-362-3p and miR-3087-3p) have putative binding sites in mRNAs 
implicated in purine metabolism, including Polr3k, Polr3f, Dck, Pde4b, Pde7b, Pfas and 
Prps2 (Supplemental Table 4). 
MicroRNA analysis by RT-qPCR revealed the same expression patterns that were 
observed in microRNA-Seq analysis. The expression of miR-340-5p was higher in livers 
from mice fed ERS compared to ERD (Ct values 26.7 ± 0.3 vs. 27.8 ± 0.6). The 
expression of miR-99b-5p was not different between the two diet groups (Ct values 20.3 
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± 0.2 vs. 20.3 ± 0.4), and miR-362-3p was not detectable (Ct > 30.0) (Supplemental 
Table 5). 
 
3.4 Human purine metabolites 
Concentrations of purine metabolites followed the same pattern in the urine of dairy-
avoiding (DA) human adults compared to the liver patterns observed in the ERD mice. 
When purines were analyzed by colorimetric assays, HPLC and HILIC-MRM-MS/MS, 
urinary concentrations of AMP and plasma concentrations of GMP were significantly 
higher in DA than in DC (Figure 3). While 21 purine metabolites excretion and/or 
concentrations were also elevated in DA, these differences were not significantly 
different from those in DC (Supplemental Figure 4). The excretion of creatinine was not 
statistically different in DA and DC (P > 0.10).  
When infant urine samples were analyzed by HPLC and colorimetric assays, uric acid 
and inosine were significantly higher in group SF and lower in group HM and MF 
(Figure 4). The concentrations of 12 out of 21 purine metabolites analyzed in infant urine 
samples by using HILIC-MRM-MS/MS were significantly higher in SF compared to HM 
and MF (Table 1). The excretion of creatinine was not statistically different among SF, 
HM and MF (P > 0.10). 
 
4. Discussion 
Evidence is accumulating that exosomes and their RNA cargos in milk are bioavailable 
(8-13, 40). In a previous study, consumption of the ERD diet caused an about 60% 
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decrease in miR-29b and miR-200c concentrations in murine plasma compared with mice 
fed the ERS diet (8). Phenotypes associated with the dietary depletion of milk exosomes 
and their RNA cargos remain elusive. To the best of our knowledge, this is the first report 
linking the dietary depletion of milk exosomes with a physiologically important 
metabolic phenotype, namely: (1) a shift in hepatic purine biochemical pathways, and (2) 
an increase in the concentrations of purine metabolites in tissues and body fluids 
compared to controls fed milk exosome-sufficient diets. 
Changes in purine metabolism have exceptional biological significance because of the 
essential roles of purines in major pathways in intermediary metabolism and in cell 
signaling (20). The roles of ATP and adenosine in purinergic receptor signaling in 
cognitive performance is of particular interest, and ongoing research in our laboratory 
suggests that spatial learning and memory is impaired in mice fed ERD compared to ERS 
controls (41). It is widely acknowledged that purinergic receptor signaling plays 
important roles in spatial learning and memory (42, 43). Herein, we made the novel 
observation of significantly higher urinary purine metabolites in soy-fed infants.   Further 
studies are needed to fully determine if there are direct linkages between limited postnatal 
milk intake, purine biochemistry and brain development.  
It is particularly noteworthy that the same purine metabolic phenotype was 
consistently observed in three independent experimental situations, i.e., mice fed ERD or 
ERS diets, DA versus DC human adults, and infants fed SF, HM or MF. While it can be 
challenging to model human disease and nutrition on animal studies (44, 45), this study 
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established cause-and-effect in animal feeding studies and translated the findings in 
animal studies to human adults and infants.  
The diets used in mouse feeding studies are based on the AIN-93G formula and are 
defined by their RNA content in the milk exosomes added to the diet (8, 22). We 
formally excluded differences in dietary purines as confounders in this study. Recently, 
we demonstrated that ERD and ERS differ by their content of milk exosomes and that the 
exosomes in the ERD diet are depleted of RNA compared to the exosomes in the ERS 
diet (S. Sukreet and J. Zempleni, unpublished observation). The amount of bovine milk 
exosomes added to the diets is the equivalent of exosomes in 0.5 L milk consumed by a 
human adult. The diets consumed by the two human cohorts in this study were less 
stringently controlled than the murine diets and yet the same patterns in purine 
metabolism was evident in humans. 
Five independent laboratories, including ours, have demonstrated that milk exosomes 
are transported by intestinal cells, immune cells and vascular endothelial cells and are 
bioavailable in mice (11-14, 40, 46, 47). These observations have gone undisputed. In 
contrast, concerns were raised by Laubier et al. (48), Auerbach et al. (49), Title et al. (50) 
and Kang et al. (51) as to whether the low concentrations of microRNAs in bovine milk 
exosomes can elicit phenotypes in non-bovine species. Laubier et al. fostered wild-type 
pups to transgenic mice that overexpressed miR-30b and failed to see a substantial 
increase in tissue levels of miR-30b in pups (48). The failure to observe an increase in 
miR-30b in pup tissues was probably due to the fact that the miR-30b in overexpression 
dams was not encapsulated in milk exosomes, thereby compromising miR-30b stability 
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and bioavailability (11, 16-18). Auerbach et al. reported a failure to detect bovine miR-
29b and miR-200c in human plasma following a milk meal (49). Subsequent studies 
suggest that the integrity of the samples used in that study was compromised and the 
RNA was degraded (10). Title et al. detected only trace amounts of miR-375 in the 
plasma of miR-375 knockout mouse pups fostered to wild-type dams (50). Our studies 
suggest that miR-375 in milk, unlike many other microRNAs, is subject to “first passage 
elimination” in intestinal mucosa and liver and therefore its concentrations in circulation 
and peripheral tissues are low ((52, 53), S. Manca and J. Zempleni, unpublished). Kang et 
al. conducted a meta-analysis of published RNA-Seq datasets and concluded that the 
abundance of dietary microRNAs in body fluids is very low and possibly due to assay 
artifacts (51). Their analysis is biased by applying considerably lower levels of stringency 
when mapping human microRNAs (3 mismatches allowed) compared to dietary 
microRNAs (1 mismatch), by disregarding the abundance of microRNAs in foods, by 
withholding details of data normalization protocols across datasets, and by dismissing the 
possibility that local concentrations of dietary microRNAs at the site of absorption might 
be high. 
Some uncertainties remain. For example, we do not know how exosomes and their 
cargos alter purine metabolism. The binding of microRNAs to binding sites in mRNAs 
implicated in purine metabolism is a plausible mechanism, but the evidence in support of 
this theory is circumstantial and based on in silico predictions. Alternative scenarios 
include the docking of exosomes to the cell surface triggering cell signaling cascades and 
exosome-dependent changes in the gut microbiome and microbial metabolites (54-56). 
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Another limitation of our study is the expression of mRNAs and microRNAs was 
assessed only in female but not in male livers. Note that we did not observe any effects of 
sex on the hepatic concentrations of purine metabolites in mice. This observation is 
consistent with a previous report suggesting that sex does not affect the hepatic 
expression of mRNAs encoding enzymes in purine metabolism in mice (57). 
 Ongoing and future work in our laboratory focuses on the bioavailability and 
distribution of microRNAs implicated in brain function and the roles of milk exosomes 
and their RNA cargos in spatial learning and memory. For example, we have observed 
that spatial memory is impaired in young female mice born to parents fed the ERD diet 
and continued on the parental diet compared with ERS controls. We speculate that altered 
purinergic receptor signaling plays a role in loss of spatial learning and memory in mice 
fed the ERD diet compared with ERS controls since adenosine and ATP play crucial 
roles in purinergic receptor signaling (42). Urine patterns of purine-relevant metabolites 
in low milk-consuming adults and infants were consistent with those predicted from basic 
research studies in mice fed ERD.  This strongly supports the idea that delivery of RNA 
cargoes from milk exosomes is a fundamental mammalian process with potentially 
profound impacts on physiology and development. 
 
Acknowledgments 
The authors acknowledge the use of the Biomedical and Obesity Research Core in the 
Nebraska Center for the Prevention of Obesity Disease through Dietary Molecules (NIH 
45	  
	  







1. Yanez-Mo M, Siljander PR, Andreu Z, Zavec AB, Borras FE, Buzas EI, Buzas K, 
Casal E, Cappello F, Carvalho J, et al. Biological properties of extracellular vesicles 
and their physiological functions. J Extracell Vesicles 2015;4:27066. 
2. Abels ER, Breakefield XO. Introduction to Extracellular Vesicles: Biogenesis, 
RNA Cargo Selection, Content, Release, and Uptake. Cell Mol Neurobiol 
2016;36:301. 
3. Svensson KJ, Christianson HC, Wittrup A, Bourseau-Guilmain E, Lindqvist E, 
Svensson LM, Morgelin M, Belting M. Exosome uptake depends on ERK1/2-heat 
shock protein 27 signaling and lipid Raft-mediated endocytosis negatively regulated 
by caveolin-1. J Biol Chem 2013;288:17713-24. 
4. Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, Mills AA, 
Elledge SJ, Anderson KV, Hannon GJ. Dicer is essential for mouse development. 
Nat Genet 2003;35:215-7. 
5. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are 
conserved targets of microRNAs. Genome Res 2009;19:92-105. 
6. Vojtech L, Woo S, Hughes S, Levy C, Ballweber L, Sauteraud RP, Strobl J, 
Westerberg K, Gottardo R, Tewari M, et al. Exosomes in human semen carry a 
distinctive repertoire of small non-coding RNAs with potential regulatory functions. 
Nucleic Acids Res 2014;42:7290-304. 
7. Danielson KM, Das S. Extracellular Vesicles in Heart Disease: Excitement for the 




8. Baier SR, Nguyen C, Xie F, Wood JR, Zempleni J. MicroRNAs are absorbed in 
biologically meaningful amounts from nutritionally relevant doses of cow’s milk 
and affect gene expression in peripheral blood mononuclear cells, HEK-293 kidney 
cell cultures, and mouse livers. J Nutr 2014;144:1495-500. 
9. Shu J, Chiang K, Zempleni J, Cui J. Computational characterization of exogenous 
microRNAs that can be transferred into human circulation. PLoS One 
2015;10:e0140587. 
10. Wang L, Sadri M, Giraud D, Zempleni J. RNase H2-Dependent Polymerase Chain 
Reaction and Elimination of Confounders in Sample Collection, Storage, and 
Analysis Strengthen Evidence That microRNAs in Bovine Milk Are Bioavailable in 
Humans. J Nutr 2018;148:153-9. 
11. Wolf T, Baier SR, Zempleni J. The intestinal transport of bovine milk exosomes is 
mediated by endocytosis in human colon carcinoma caco-2 cells and rat small 
intestinal IEC-6 cells. J Nutr 2015;145:2201-6. 
12. Izumi H, Tsuda M, Sato Y, Kosaka N, Ochiya T, Iwamoto H, Namba K, Takeda Y. 
Bovine milk exosomes contain microRNA and mRNA and are taken up by human 
macrophages. J Dairy Sci 2015;98:2920-33. 
13. Kusuma Jati R, Manca S, Friemel T, Sukreet S, Nguyen C, Zempleni J. Human 
vascular endothelial cells transport foreign exosomes from cow’s milk by 
endocytosis. . Am J Physiol Cell Physiol 2016;310:C800-C7. 
14. Munagala R, Aqil F, Jeyabalan J, Gupta RC. Bovine milk-derived exosomes for 




15. Wang K, Li H, Yuan Y, Etheridge A, Zhou Y, Huang D, Wilmes P, Galas D. The 
complex exogenous RNA spectra in human plasma: an interface with human gut 
biota? PLoS One 2012;7:e51009. 
16. Izumi H, Kosaka N, Shimizu T, Sekine K, Ochiya T, Takase M. Bovine milk 
contains microRNA and messenger RNA that are stable under degradative 
conditions. J Dairy Sci 2012;95:4831-41. 
17. Benmoussa A, Lee CH, Laffont B, Savard P, Laugier J, Boilard E, Gilbert C, Fliss 
I, Provost P. Commercial dairy cow milk microRNAs resist digestion under 
simulated gastrointestinal tract conditions. J Nutr 2016;146:2206-15. 
18. Zempleni J, Aguilar-Lozano A, Sadri M, Sukreet S, Manca S, Wu D, Zhou F, Mutai 
E. Biological activities of extracellular vesicles and their cargos from bovine and 
human milk in humans and implications for infants. J Nutr 2017;147:3-10. 
19. Luo Y, Wang P, Wang X, Wang Y, Mu Z, Li Q, Fu Y, Xiao J, Li G, Ma Y, et al. 
Detection of dietetically absorbed maize-derived microRNAs in pigs. Sci Rep 
2017;7:645. 
20. Garrett RH, Grisham CM. Biochemistry. Fort Worth, TX: Saunders College 
Publishing; 1995. 
21. Couzin-Frankel J. When mice mislead. Science 2013;342:922-3, 5. 
22. Reeves PG, Nielsen FH, Fahey GC, Jr. AIN-93 purified diets for laboratory rodents: 
final report of the American Institute of Nutrition ad hoc writing committee on the 




23. Leiferman A, Shu J, Grove R, Cui J, Adamec J, Zempleni J. A diet defined by its 
content of bovine milk exosomes and their RNA cargos has moderate effects on 
gene expression, amino acid profiles and grip strength in skeletal muscle in 
C57BL/6 mice. J Nutr Biochem 2018 (in press) 
24. Andres A, Casey PH, Cleves MA, Badger TM. Body fat and bone mineral content 
of infants fed breast milk, cow's milk formula, or soy formula during the first year 
of life. J Pediat 2013;163:49-54. 
25. Nygren H, Seppanen-Laakso T, Castillo S, Hyotylainen T, Oresic M. Liquid 
chromatography-mass spectrometry (LC-MS)-based lipidomics for studies of body 
fluids and tissues. Methods Mol Biol 2011;708:247-57. 
26. Smith CA, O'Maille G, Want EJ, Qin C, Trauger SA, Brandon TR, Custodio DE, 
Abagyan R, Siuzdak G. METLIN: a metabolite mass spectral database. Ther Drug 
Monit 2005;27:747-51. 
27. Xia J, Wishart DS. Using MetaboAnalyst 3.0 for Comprehensive Metabolomics 
Data Analysis. Curr Protoc Bioinformatics 2016;55:14 0 1- 0 91. 
28. Yuan M, Breitkopf SB, Yang X, Asara JM. A positive/negative ion-switching, 
targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, 
and fresh and fixed tissue. Nat Protoc 2012;7:872-81. 
29. Burdett TC, Desjardins CA, Logan R, McFarland NR, Chen X, Schwarzschild MA. 
Efficient determination of purine metabolites in brain tissue and serum by high-
performance liquid chromatography with electrochemical and UV detection. 




30. Husdan H, Rapoport A. Estimation of creatinine by the Jaffe reaction. A 
comparison of three methods. Clin Chem 1968;14:222-38. 
31. FastQC [database on the Internet] 2017 [cited 8/24/2017]. Available from: 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/. 
32. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data 
with or without a reference genome. BMC Bioinformatics 2011;12:323. 
33. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with 
RNA-Seq. Bioinformatics 2009;25:1105-11. 
34. Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L. 
Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat 
Biotechnol 2013;31:46-53. 
35. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion 
for RNA-seq data with DESeq2. Genome Biol 2014;15:550. 
36. Sun Z, Evans J, Bhagwate A, Middha S, Bockol M, Yan H, Kocher JP. CAP-
miRSeq: a comprehensive analysis pipeline for microRNA sequencing data. BMC 
Genomics 2014;15:423. 
37. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs 
using deep sequencing data. Nucleic Acids Res 2014;42:D68-D73. 
38. Heintz-Buschart A, Yusuf D, Kaysen A, Etheridge A, Fritz JV, May P, de Beaufort 
C, Upadhyaya BB, Ghosal A, Galas DJ, et al. Isolation of nucleic acids from low 





39. Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target 
interactions. Nat Methods 2015;12:697. 
40. Chen T, Xie MY, Sun JJ, Ye RS, Cheng X, Sun RP, Wei LM, Li M, Lin DL, Jiang 
QY, et al. Porcine milk-derived exosomes promote proliferation of intestinal 
epithelial cells. Sci Rep 2016;6:33862. 
41. Mutai E, Zhou F, Zempleni J. Depletion of dietary bovine milk exosomes impairs 
sensorimotor gating and spatial learning in C57BL/6 mice. FASEB J 2017;31:150.4 
[peer-reviewed meting abstract]. 
42. Duster R, Prickaerts J, Blokland A. Purinergic signaling and hippocampal long-term 
potentiation. Curr Neuropharmacol 2014;12:37-43. 
43. Burnstock G, Krugel U, Abbracchio MP, Illes P. Purinergic signalling: from normal 
behaviour to pathological brain function. Prog Neurobiol 2011;95:229-74. 
44. McGonigle P, Ruggeri B. Animal models of human disease: challenges in enabling 
translation. Biochem Pharmacol 2014;87:162-71. 
45. Baker DH. Animal models in nutrition research. J Nutr 2008;138:391-6. 
46. Agrawal AK, Aqil F, Jeyabalan J, Spencer WA, Beck J, Gachuki BW, Alhakeem 
SS, Oben K, Munagala R, Bondada S, et al. Milk-derived exosomes for oral 
delivery of paclitaxel. Nanomedicine 2017;13:1627-36. 
47. Liao Y, Du X, Li J, Lonnerdal B. Human milk exosomes and their microRNAs 





48. Laubier J, Castille J, Le Guillou S, Le Provost F. No effect of an elevated miR-30b 
level in mouse milk on its level in pup tissues. RNA Biol 2015;12:26-9. 
49. Auerbach A, Vyas G, Li A, Halushka M, Witwer K. Uptake of dietary milk 
miRNAs by adult humans: a validation study. F1000Res 2016;5:721. 
50. Title AC, Denzler R, Stoffel M. Uptake and function studies of maternal milk-
derived microRNAs. J Biol Chem 2015;290:23680-91. 
51. Kang W, Bang-Berthelsen CH, Holm A, Houben AJ, Muller AH, Thymann T, 
Pociot F, Estivill X, Friedlander MR. Survey of 800+ data sets from human tissue 
and body fluid reveals xenomiRs are likely artifacts. RNA 2017;23:433-45. 
52. Pond SM, Tozer TN. First-pass elimination. Basic concepts and clinical 
consequences. Clin Pharmacokinet 1984;9:1-25. 
53. Zempleni J, Baier SR, Hirschi K. Diet-responsive microRNAs are likely exogenous. 
J Biol Chem 2015;290:25197. 
54. Purushothaman A, Bandari SK, Liu J, Mobley JA, Brown EE, Sanderson RD. 
Fibronectin on the Surface of Myeloma Cell-derived Exosomes Mediates Exosome-
Cell Interactions. J Biol Chem 2016;291:1652-63. 
55. Muller L, Mitsuhashi M, Simms P, Gooding WE, Whiteside TL. Tumor-derived 
exosomes regulate expression of immune function-related genes in human T cell 
subsets. Sci Rep 2016;6:20254. 
56. Zhou F, Paz AH, Sadri M, Fernando CS, Zempleni J. A diet defined by its content 
of bovine milk exosomes alters the composition of the intestinal microbiome in 




57. Gatti DM, Zhao N, Chesler EJ, Bradford BU, Shabalin AA, Yordanova R, Lu L, 



























































































































































































































































FIGURE 1 Hepatic metabolome in female mice fed ERD or ERS diets for 4 weeks. (A) 
Heat map with top 25 differential liver metabolites between ERD and ERS diets. (B) 
Principal Component Analysis (PCA) leveraging 191 polar metabolites indicates clear 
separation of mice by their diet treatment group. PC 1 and PC2 explain 69% and 15%, 
respectively, of the variance. Clusters defined by ERD and ERS diets are shown, with 
each symbol representing the Scores Plot value for each mouse. Ovals depict 95% of 
confidence interval (C) Diet-dependent purine metabolites in mouse livers. Values are 
means ± SEM. aP < 0.05 vs ERS (n = 4-5 mice per group in all panels). Abbreviations:  
ERD, exosome and RNA-depleted; ERS, exosome and RNA-sufficient; PC, principal 





FIGURE 2 Transcriptomic analysis in female mice fed ERD and ERS for 4 weeks. 
Panels depict mRNA (A) Heat map with top 25 differentially expressed transcripts in 
livers between ERD and ERS diets. (B) Differentially abundant microRNAs in mouse 
livers between ERD and ERS diets. aP < 0.05 vs ERS (n = 5 mice per group in all panels). 





















































































































FIGURE 3 Urinary concentration of AMP and plasma concentration of GMP in adult 
human DA and DC. Values are means ± SEM, corrected for creatinine. aP < 0.05 vs DC 
(n = 6 adults per group). Abbreviations: AMP, adenosine monophosphate; DA, dairy 























































FIGURE 4 Purine metabolites in urine samples from infants, ages 3 months, fed SF, MF 
or HM. Values are means ± SEM. aP < 0.05 vs groups HM and SF, bP < 0.05 vs groups 
HM-MF and SF (n = 46 for SF, 40 for HM and 40 for MF). Abbreviations: HM, human 






















































TABLE 1 Differential expression of mRNAs involved in purine metabolism in livers 
from mice fed ERD or ERS diets for four weeks. 1 
mRNA ERD ERS 
   FPKM   
Ak12 9.0 ± 19.6 0.1 ± 0.1 
Pde4d 1.2 ± 0.8  0.7 ± 0.1 
Nt5c3b 2.4 ± 0.3 * 1.5 ± 0.1 
Ada 1.0 ± 0.2 * 0.6 ± 0.2 
Pole 0.3 ± 0.1 * 0.2 ± 0.1 
Nudt16l1 12.1 ± 0.8 * 10.3 ± 1.4 
Nme6 19.3 ± 3.3 * 25.4 ± 3.2 
Entpd7 1.1 ± 0.3 * 1.8 ± 0.3 
Enpp3 9.0 ± 1.4 * 12.5 ± 2.8 
Polr1b 5.0 ± 0.4 * 6.1 ± 0.5 
Ak4 5.5 ± 0.4 * 7.6 ± 1.9 
1Values are means ± SD (n = 5 mice per group). Values represent FPKM. 
2Abbreviations: Ada, adenosine deaminase; Ak1, adenylate kinase 1; Ak4, adenylate 
kinase 4; Enpp3, ectonucleotide pyrophosphatase/phosphodiesterase family member 1/3; 
Entpd7, ectonucleoside triphosphate diphosphohydrolase 7; FPKM, fragments per 
kilobase million; Nme6, nucleoside diphosphate kinase 6; Nt5c3b, 5'-nucleotidase, 
cytosolic IIIB; Nudt16l1,	  (nucleoside diphosphate linked moiety X)-type motif 16-like 1; 
Pde4d, phosphodiesterase 4D, CAMP-specific; Pole, DNA polymerase epsilon subunit 1; 
Polr1b, DNA-directed RNA polymerase I subunit RPA2. 





TABLE 2 Purine metabolites in infants fed SF, HM or MF.1 
 
Metabolite Multiplier2 SF HM MF 
  Peak Intensity 
Adenosine 1,000,000 242 ± 129b 135 ± 71 167.3 ± 78.2 
ADP3 1,000 34 ± 27b 7 ± 5 10.6 ± 6.6 
AICAR3 10,000 92 ± 293 3 ± 2 10.2 ± 10.0 
Allantoin 100,000 13 ± 14 9 ± 10 7.7 ± 6.3 
AMP3 100,000 21 ± 39b 1 ± 1 1.6 ± 1.5 
ATP3 100,000 12 ± 26 0.1 ± 0.1 0.0 ± 0.0 
cAMP3 100,000 88 ± 79b  35 ± 25 51 ± 33 
GDP3 1,000 57 ± 52b 32 ± 22 31 ± 26 
GMP3 1,000 60 ± 52b 10 ± 9 22 ± 26 
GTP3 1,000 69 ± 51b 9 ± 9 34 ± 33 
Guanine 1,000,000 68 ± 38b 35 ± 20 45 ± 21 
Guanosine 10,000 29 ± 22b 14 ± 8 20 ± 9 
Hypoxanthine 1,000,000 84 ± 73a 75 ± 51 91 ± 47 
IMP3 10,000 21 ± 25b 3 ± 3 6 ± 6 
Inosine 1,000,000 14 ± 9b 12 ± 7 14 ± 10 
PRPP3 100,000 32 ± 21b 14 ± 10 28 ± 16 
Uric acid 1,000,000 166 ± 179b 40 ± 35 63 ± 52 
Xanthine 1,000,000 83 ± 50a 77 ± 48 81 ± 67 
Xanthosine 1,000,000 17 ± 23b 5 ± 3 7 ± 8 
XMP3 100 77 ± 79a 12 ± 13 31 ± 19 
1Values are means ± SD (n = 13 for SF, 14 for HM and 13 for MF). Values represent 
peak intensities normalized by the total number of peaks and per mmol creatinine. 
2Multiplication factor to be used to calculate the peak counts. 
3Abbreviations: ADP, adenosine diphosphate; AICAR, 5-aminoimidazole-4-carboxamide 




cyclic adenosine monophosphate; GDP, guanosine diphosphate; GMP, guanosine 
monophosphate; GTP, guanosine triphosphate; IMP, inosine monophosphate; PRPP, 5-
phospho-α-D-ribosyl 1-pyrophosphate; XMP, xanthosine monophosphate.  
aP < 0.05 vs groups HM and SF. 






SUPPLEMENTAL FIGURE 1 Body weight, fat mass and lean body mass in female 
mice, age 7 weeks, fed ERD or ERS for 4 weeks. Values are means ± SEM (n = 5 mice 

































































SUPPLEMENTAL FIGURE 2 Metabolite set enrichment analysis of hepatic 
metabolites in female mice fed ERD or ERS diets for 4 weeks (n = 4-5 mice per group). 
Abbreviations: ERD, exosome and RNA-depleted; ERS, exosome and RNA-sufficient.  
OXIDATION OF BRANCHED CHAIN FATTY ACIDS 
BETA OXIDATION OF VERY LONG CHAIN FATTY ACIDS 
PURINE METABOLISM 
PHENYLALANINE AND TYROSINE METABOLISM 
PROTEIN BIOSYNTHESIS 
VALINE, LEUCINE AND ISOLEUCINE DEGRADATION 
PYRIMIDINE METABOLISM 




EXITATORY NEURAL SIGNALLING THROUGH 5-HTRs AND SEROTONIN 
CORTICOTROPIN ACTIVATION OF CORTISOL PRODUCTION  
VASOPRESSIN REGULATION OF WATER HOMEOSTASIS 
INTRACELLULAR SIGNALING THROUGH FSH AND LHCGR RECEPTORS  
INTRACELLULAR SIGNALING THROUGH HISTAMINE H2 RECEPTOR 
AMMONIA RECYCLING 
GLYCOLISIS 
CITRIC ACID CYCLE 
GLUCONEOGENESIS 
MITOCHONDRIAL ELECTRON TRANSPORT CHAIN 
TYROSINE METABOLISM 
CATECHOLAMINE BIOSYNTHESIS 
INTRACELLULAR SIGNALING THROUGH PGD2 RECEPTOR AND PG D2 
INTRACELLULAR SIGNALING - PROSTACYCLIN RECEPTOR 





PANTOTHENATE AND COA BIOSYNTHESIS 
STARCH AND SUCROSE METABOLISM 
FRUCTOSE AND MANNOSE DEGRADATION 
P value 
Fold Enrichment 






SUPPLEMENTAL FIGURE 3 Effects of exosome and RNA-defined diets on hepatic 
concentrations of targeted purine metabolites in mice. Values are means ± SEM. *P < 
0.05 vs ERS (n = 5 mice each in groups ERD and ERS). Abbreviations: ADP, Adenosine 
diphosphate; cAMP, Cyclic Adenosine monophosphate; ERD, exosome and RNA-
























































































































































SUPPLEMENTAL FIGURE 4 Purine metabolites in urine and plasma of DA and DC. 
Values are presented as means ± SEM. (0.07 < P < 0.47; n = 6 adults per group). 























































































































































































































































































































































































































































































































SUPPLEMENTAL TABLE 1 Purine metabolites in female and male mice livers fed 
ERD and ERS diets. 
 
Metabolite Multiplier2           Female ERD and ERS    Male ERD and ERS 
 _____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 Peak intensities 
Adenosine   10,000,000        93 ± 37       84 ± 53 
Xanthosine   10,000,000        15 ± 3       15 ± 6 
AMP   10,000,000        37 ± 13       32 ± 20 
IMP   1,000,000        27 ± 11       25 ± 18 
cAMP   10,000        22 ± 4       27 ± 9 
GMP   10,000        22 ± 15       19 ± 10 
Xanthine   10,000,000        44 ± 7       42 ± 6 
Guanosine   100,000        13 ± 1       15 ± 6 
Xanthine   10,000,000        44 ± 7       42 ± 6 
GTP   1,000        12 ± 5       14 ± 5 
 
1Values are means ±SD (n = 10 mice per group). Values represent peak intensities 
normalized by the total number of peaks.  





SUPPLEMENTAL TABLE 2 Cohorts of dairy consumers (DC) and dairy avoiders 
(DA). 
 ___________________________________________  
_  
Variable DC DA      
 
 
n (M/Fa) 6 (3/3) 6 (4/2) 
Age (years) 32 ± 9.4 36.8 ± 14.6 
BMI (kg/m2) 22.8 ± 1.6 23.5 ± 3.9 
 ______________________________________________________________________________________  







SUPPLEMENTAL TABLE 3 Purine metabolites in milk used for preparing the ERD 
and ERS diets in mouse feeding studies. 
 
Metabolite ERD ERS 
 µmol/L 
Hypoxanthine 1.08 ± 0.281 0.87 ± 0.22 
Inosine 5.44 ± 1.04 6.06 ± 0.79 
1Values are means ±SD (n = 3 batches per group). ERD and ERS diets contain 200 mL 
of milk in 1 kg diet. Three samples were analyzed, using separate batches of both ERD 






SUPPLEMENTAL TABLE 4 Hepatic expression of microRNAs (Tab 1) mRNA (Tab 
2) in murine livers, and predictions of microRNA-







SUPPLEMENTAL TABLE 5 Abundance of hepatic miRNAs in mice fed the ERD and 
ERS diets for four weeks  
 
miRNA ERD ERS 
                                        Relative Abundance 
miR-340-5p  0.73 ± 0.10* 1.02 ± 0.26 
miR-99b-5p  1.80 ± 0.92 1.05 ± 0.44 
miR-362-3p                 not detectable 
1Values are means ±SD (n = 5 mice per group) of RT-qPCR analysis. 







The theory of dietary exogenous miRNAs having physiological effects in the consumer is 
of great importance and hence at great debate. The diverse studies conducted in our lab 
support this theory and consistently evidence that bovine exosomes and their miRNA 
cargos are transferred into the host system and in mice, certain phenotypes can be 
observed.  
The results from this thesis strongly support the theory by displaying differences in 
purine metabolite concentration and enzymatic gene expression, not only in mice, but 
also in adults and infants upon dairy avoidance. Nevertheless, there are multiple 
approaches that could keep strengthening the theory and complement it by determining 
the possible specific interactions that could be occurring between the host and the 
exogenous bovine milk exosomes and their RNA cargos.  
Utilizing high-throughput approaches to understand the differential network of 
interactions occurring between ERD and ERS could help to determine which components 
and specific miRNAs could be driving to the phenotypic purine change among the two 
diets. Determining these important nodes could lead to link the nodes with different 
conditions that are triggered upon the possible disruption of these nodes, for instance, 
cognitive impairment, cancer development, possible infertility, among others. Numerous 
studies could be developed to determine these possible interactions in an effective 
manner, such as stable isotope studies and CLASH or HITS-CLIP.  
As for humans, epidemiological studies could be performed to determine the link 




development of neurological diseases, diabetes, cardiovascular conditions and cancer. 
Assessing the chronic gene expression changes upon consuming dairy products could 
translate into possible recommendations with proven rationale for milk intake, such as a 
beneficial chronic modification in gene expression.  
In infants, performing experiments to deeply analyze the different diets with high-
throughput and subsequent confirmatory experiments could enable to determine the 
possible candidates in human breast milk and cow´s milk that lead to lower profiles of 
purine metabolites.  
Subsequently, with models and experiments that could link the amount of exosomes or 
their miRNAs with the concentration for purine metabolites in infants urines could 
strengthen the theory that exosomes and their miRNA cargoes from human or bovine 
milk are beneficial for human health. These correlations could enable the research field to 
fortify cow’s milk and soy formula with this components that could drive the differential 
metabolomic phenotype to avoid possible future disease development of this well-known 





Hepatic	  non-­‐targeted	  metabolome	  in	  female	  mice	  fed	  ERD	  or	  ERS	  diet	  for	  4	  weeks	  
Sample	   1	   2	   3	   4	   1	   2	   3	   4	   5	  
Phenotype	   ERD	   ERD	   ERD	   ERD	   ERS	   ERS	   ERS	   ERS	   ERS	  
Metabolite	   Peak	  Intensities	  (10^5)	  
(-­‐)-­‐beta-­‐Phellandrene	   3.1	   2.0	   2.8	   2.3	   1.9	   1.6	   1.4	   1.1	   1.1	  
(R)-­‐S-­‐
Lactoylglutathione	   4.0	   1.4	   3.1	   3.5	   2.1	   0.7	   1.2	   0.8	   1.5	  
1,4-­‐beta-­‐D-­‐Glucan	   26.6	   15.5	   24.8	   31.1	   19.3	   13.0	   12.4	   13.1	   15.6	  
2-­‐
Methylbutyroylcarnit
ine	   3.6	   3.6	   2.3	   3.3	   1.2	   1.5	   1.9	   1.4	   1.3	  
2-­‐
Methylbutyrylglycine	   0.8	   0.5	   0.6	   0.8	   0.7	   0.5	   0.5	   0.4	   0.4	  
dGMP	   9.1	   10.6	   10.4	   12.4	   14.7	   19.7	   20.7	   19.5	   24.9	  
C22H40O11	   7.3	   7.2	   6.1	   5.7	   10.8	   20.7	   15.1	   16.7	   13.7	  
4-­‐(4-­‐Deoxy-­‐alpha-­‐D-­‐
gluc-­‐4-­‐enuronosyl)-­‐
D-­‐galacturonate	   1.5	   1.3	   1.6	   2.0	   1.0	   1.2	   0.9	   0.9	   1.1	  
5-­‐Methylcytidine	   4.2	   2.6	   3.3	   2.1	   1.8	   1.7	   1.4	   1.2	   1.2	  
6-­‐Methylthioguanine	   0.3	   0.3	   0.3	   0.3	   0.4	   0.6	   0.5	   0.4	   0.4	  
Acetylcarnitine	   23.1	   17.6	   17.1	   20.2	   5.8	   5.6	   6.3	   7.8	   4.2	  
Adenosine	   18.6	   16.5	   11.9	   12.8	   8.9	   8.0	   13.2	   7.0	   9.7	  
AMP	   2.5	   1.9	   2.3	   1.9	   1.7	   0.9	   0.9	   1.0	   1.5	  
Adenosine	  
monophosphate	   247	   119	   99	   136	   116	   94	   93	   52	   74	  
ADP	   11.3	   6.9	   6.1	   6.6	   4.5	   3.4	   4.2	   2.1	   3.6	  
ADP-­‐ribose	   161	   110	   126	   116	   69	   61	   68	   51	   61	  
Alanine	   0.3	   0.5	   0.3	   0.2	   0.0	   0.0	   0.0	   0.0	   0.0	  
Asn-­‐Asp-­‐OH	   12.5	   5.7	   7.2	   9.0	   5.9	   2.3	   3.0	   2.3	   3.9	  
Asn-­‐Met-­‐OH	   2.6	   2.8	   2.7	   2.5	   6.1	   5.8	   7.4	   4.8	   5.0	  
Asp-­‐Asp-­‐OH	   0.5	   0.2	   0.3	   0.4	   0.2	   0.2	   0.1	   0.1	   0.1	  
Asparaginyl-­‐Proline	   3.9	   2.7	   3.6	   2.8	   2.4	   2.2	   2.0	   1.6	   1.7	  
Asparaginyl-­‐Tyrosine	   0.4	   0.4	   0.3	   0.3	   0.3	   0.3	   0.3	   0.2	   0.2	  
Butyrylcarnitine	   1.1	   1.2	   0.9	   1.0	   0.3	   0.3	   0.6	   0.2	   0.2	  
cAMP	   1.1	   0.7	   0.8	   1.0	   0.7	   0.7	   0.7	   0.6	   0.6	  
Coenzyme	  A	   8.5	   7.2	   5.1	   6.5	   14.8	   20.5	   19.5	   12.8	   19.6	  
Cyclamic	  acid	   3.3	   1.9	   1.5	   1.7	   1.4	   1.2	   0.9	   0.5	   0.6	  
Cysteinylglycine	   0.6	   0.4	   0.5	   0.7	   0.5	   0.5	   0.4	   0.4	   0.4	  
HO	  AKG	   0.8	   1.0	   1.3	   1.6	   2.7	   4.1	   3.6	   3.1	   2.8	  
D-­‐4'-­‐
Phosphopantothenat
e	   2.1	   1.8	   3.7	   2.3	   1.3	   1.0	   0.7	   1.2	   2.0	  
D-­‐Cysteine	   0.4	   0.4	   0.3	   0.3	   0.3	   0.1	   0.2	   0.1	   0.2	  
dGDP	   3.1	   3.6	   3.1	   4.2	   7.0	   10.6	   9.8	   7.2	   9.9	  
Dephospho-­‐CoA	   25	   26	   28	   23	   36	   42	   33	   37	   55	  
Diacylglycerol	   0.5	   0.4	   0.4	   0.3	   0.6	   1.0	   0.7	   0.9	   0.7	  
dIDP	   1.4	   1.2	   1.3	   1.4	   0.9	   1.0	   0.7	   0.8	   0.8	  




FMN	   4.0	   4.2	   3.9	   4.9	   5.2	   7.0	   7.3	   6.5	   7.3	  
Gamma-­‐
Glutamylglutamine	   4.0	   2.2	   2.9	   3.0	   2.2	   1.1	   1.4	   1.1	   1.7	  
gamma-­‐L-­‐Glutamyl-­‐
L-­‐cysteinyl-­‐beta-­‐
alanine	   4.1	   1.7	   3.2	   2.9	   2.1	   1.5	   1.4	   1.1	   1.0	  
GDP-­‐L-­‐fucose	   4.8	   1.6	   1.9	   3.0	   2.0	   0.9	   1.1	   0.4	   0.5	  
Genistein	  7-­‐O-­‐
glucoside-­‐6''-­‐
malonate	   0.3	   0.6	   0.5	   1.0	   0.9	   1.1	   0.9	   1.4	   2.0	  
Genistin	  6''-­‐O-­‐
acetate	   1.0	   0.5	   0.5	   1.2	   0.4	   0.3	   0.3	   0.3	   0.4	  
Glutamylphenylalani
ne	   0.4	   0.3	   0.3	   0.3	   0.2	   0.1	   0.2	   0.1	   0.2	  
Glutathione	   109	   55	   77	   87	   63	   27	   38	   30	   45	  
Glycerol	  
tripropanoate	   14.8	   16.7	   14.4	   11.0	   12.0	   13.1	   10.2	   10.6	   9.6	  
Glycogen	   1.0	   0.7	   0.5	   0.8	   0.2	   0.2	   0.1	   0.5	   0.3	  
Guanosine	  
monophosphate	   94	   44	   44	   51	   42	   25	   31	   17	   27	  
Indoleglycerol	  
phosphate	   1.5	   1.0	   1.3	   1.0	   0.8	   0.7	   0.6	   0.4	   0.3	  
Inosine	   378	   280	   398	   257	   199	   164	   163	   183	   210	  
IMP	   69.7	   30.1	   37.0	   35.6	   23.1	   14.6	   16.3	   7.9	   16.0	  
Inosine-­‐5'-­‐
carboxylate	   9.2	   6.5	   8.7	   7.0	   5.5	   4.5	   4.0	   4.6	   4.8	  
Inosinic	  acid	   1.4	   0.9	   1.4	   1.4	   1.0	   0.8	   0.8	   0.8	   0.9	  
L-­‐Aspartyl-­‐L-­‐
phenylalanine	   0.3	   0.3	   0.4	   0.3	   0.3	   0.1	   0.2	   0.2	   0.2	  
L-­‐Dopa	   1.0	   1.2	   1.0	   0.9	   0.4	   0.2	   0.2	   0.1	   0.2	  
L-­‐gamma-­‐glutamyl-­‐L-­‐
isoleucine	   6.9	   7.7	   8.2	   7.0	   4.0	   4.0	   3.9	   3.2	   3.2	  
L-­‐Leucine	   1.9	   1.8	   1.5	   0.5	   0.1	   0.1	   0.1	   0.1	   0.2	  
L-­‐Phenylalanine	   10.5	   11.7	   10.4	   1.9	   0.2	   0.2	   0.2	   0.2	   0.2	  
L-­‐Tyrosine	   2.5	   2.9	   2.8	   4.1	   0.1	   0.0	   0.0	   0.0	   0.9	  
L(-­‐)-­‐Nicotine	  pestanal	   1.1	   1.3	   1.2	   0.3	   0.0	   0.0	   0.0	   0.0	   0.0	  
Leucyl-­‐Aspartate	   1.4	   1.5	   1.4	   1.1	   0.7	   0.6	   0.8	   0.5	   0.4	  
Luteolinidin	   1.4	   1.6	   1.6	   1.5	   2.5	   4.2	   3.6	   3.5	   2.9	  
N-­‐a-­‐AcCitrulline	   7.6	   4.5	   5.9	   5.1	   4.2	   3.6	   3.0	   2.5	   2.3	  
N-­‐Acetylmuramoyl-­‐
Ala	   6.2	   4.7	   3.5	   3.1	   4.7	   8.8	   6.3	   7.2	   5.8	  
N-­‐Acetylvaline	   0.8	   1.1	   0.7	   0.5	   0.2	   0.0	   0.1	   0.0	   0.1	  
N-­‐Hydroxy-­‐L-­‐tyrosine	   0.5	   0.3	   0.4	   0.5	   0.4	   0.2	   0.3	   0.3	   0.4	  
N2-­‐Succinyl-­‐L-­‐
ornithine	   0.5	   0.5	   0.4	   0.2	   0.2	   0.1	   0.1	   0.1	   0.1	  
NADH	   8.4	   4.8	   6.7	   7.2	   2.8	   4.2	   3.8	   3.2	   4.4	  
NAD	   6.4	   4.6	   3.6	   5.1	   6.4	   10.6	   10.8	   6.8	   9.4	  
Nonanoic	  acid,	  3-­‐
amino-­‐,	  (R)	   0.5	   1.0	   0.5	   0.1	   0.0	   0.1	   0.1	   0.0	   0.0	  
O-­‐Phospho-­‐4-­‐
hydroxy-­‐L-­‐threonine	   0.6	   0.6	   0.5	   0.4	   0.3	   0.2	   0.3	   0.2	   0.3	  




Oxidized	  GSH	  (+)	   253	   96	   120	   185	   115	   42	   56	   41	   65	  
Phenylalanyl-­‐
Gamma-­‐glutamate	   1.0	   1.1	   0.8	   1.0	   0.7	   0.7	   0.9	   0.6	   0.7	  
Phenylethylamine	   0.9	   0.6	   0.8	   0.7	   0.7	   0.5	   0.5	   0.5	   0.5	  
Phenylpropiolic	  acid	   0.6	   0.7	   0.7	   1.7	   0.0	   0.0	   0.0	   0.0	   0.1	  
Phosphoribosyl	  
formamidocarboxam
ide	   2.0	   1.2	   1.4	   1.5	   1.3	   1.0	   0.9	   0.9	   0.9	  
Phosphoribosylformi
minoAICAR-­‐
phosphate	   0.6	   0.3	   0.3	   0.4	   0.2	   0.2	   0.3	   0.1	   0.1	  
Quercetin	  3-­‐
(2'',3'',4''-­‐
triacetylgalactoside)	   1.1	   0.8	   1.0	   1.8	   0.3	   0.3	   0.2	   0.2	   0.3	  
Riboflavin	   1.8	   2.5	   1.9	   2.0	   2.6	   3.1	   2.7	   3.2	   3.6	  
4',5'-­‐cFMN	   10.2	   12.1	   12.6	   15.3	   19.5	   26.3	   26.6	   24.9	   31.7	  
S(Hydroxyphenylacet
othiohydroximoyl)-­‐L-­‐
cysteine	   1.3	   1.4	   1.6	   1.5	   1.1	   0.7	   0.7	   0.6	   0.8	  
SAM	   10.9	   7.7	   7.4	   7.0	   2.6	   2.5	   2.9	   3.3	   4.5	  
URIDINE	   1.5	   1.3	   1.2	   0.9	   0.4	   0.4	   0.3	   0.4	   0.3	  
Xanthine	   5.6	   5.4	   6.8	   7.0	   2.2	   3.1	   2.6	   3.2	   4.3	  
Xanthosine	   49	   45	   58	   56	   15	   22	   18	   22	   30	  
 
Purine	  Transcriptomic	  analysis	  in	  female	  mice	  livers	  
Sample	   1	   2	   3	   4	   1	   2	   3	   4	   5	  
Phenotype	   ERD	   ERD	   ERD	   ERD	   ERS	   ERS	   ERS	   ERS	   ERS	  
Gene	   FPKM	  
Ada	   0.73	   0.89	   1.17	   1.19	   0.41	   0.53	   0.82	   0.49	   0.87	  
Adcy1	   0.09	   0.08	   0.11	   0.19	   0.14	   0.24	   0.01	   0.32	   0.08	  
Adcy10	   0.00	   0.02	   0.04	   0.05	   0.19	   0.06	   0.10	   0.02	   0.05	  
Adcy2	   0.06	   0.10	   0.14	   0.04	   0.06	   0.09	   0.04	   0.02	   0.01	  
Adcy3	   0.04	   0.01	   0.05	   0.15	   0.06	   0.18	   0.17	   0.06	   0.09	  
Adcy4	   2.32	   2.12	   2.73	   2.35	   1.85	   2.36	   2.49	   2.12	   1.82	  
Adcy5	   0.29	   0.35	   0.23	   0.56	   0.35	   0.34	   0.33	   0.21	   0.28	  
Adcy6	   3.74	   3.59	   4.28	   3.84	   2.96	   5.57	   3.35	   2.98	   1.87	  
Adcy7	   1.45	   2.16	   1.84	   1.44	   1.42	   1.87	   1.38	   1.36	   1.26	  
Adcy9	   3.23	   3.43	   3.66	   2.93	   3.17	   3.04	   3.37	   2.80	   2.91	  
Adk	   432	   503	   438	   425	   516	   390	   447	   448	   653	  
Adprm	   7.54	   11.64	   10.11	   7.54	   8.61	   8.00	   10.38	   7.03	   9.87	  
Adsl	   5.45	   5.09	   5.22	   5.44	   5.46	   5.18	   5.59	   6.00	   5.86	  
Adss	   25.75	   23.77	   23.50	   24.06	   27.83	   28.86	   27.23	   24.10	   38.05	  
Adssl1	   11.78	   14.55	   10.47	   11.44	   19.38	   7.99	   14.79	   10.15	   13.21	  
Ak1	   0.13	   0.13	   0.34	   0.49	   0.27	   0.07	   0.20	   0.06	   0.11	  
Ak2	   155	   162	   162	   144	   173	   137	   161	   148	   162	  
Ak3	   183	   190	   187	   171	   188	   180	   192	   158	   215	  
Ak4	   5.34	   5.10	   5.31	   6.19	   9.94	   5.06	   7.72	   6.45	   8.71	  
Ak5	   0.02	   0.00	   0.05	   0.02	   0.00	   0.00	   0.09	   0.12	   0.02	  




Ak7	   0.00	   0.05	   0.00	   0.07	   0.00	   0.00	   0.06	   0.12	   0.07	  
Ak8	   0.00	   0.00	   0.06	   0.00	   0.09	   0.06	   0.09	   0.00	   0.07	  
Ampd2	   13.75	   13.01	   15.43	   12.29	   14.03	   21.42	   13.15	   12.90	   11.56	  
Ampd3	   0.67	   0.31	   0.46	   0.68	   0.50	   0.50	   0.33	   0.42	   0.39	  
Aprt	   17.87	   15.38	   20.47	   14.53	   19.14	   19.27	   20.07	   16.93	   21.64	  
Atic	   7.39	   6.25	   6.20	   7.15	   10.34	   4.72	   8.87	   10.27	   11.08	  
Cant1	   9.69	   8.29	   8.82	   7.24	   8.27	   9.45	   8.75	   9.09	   6.82	  
Dck	   1.36	   2.28	   1.13	   1.87	   1.20	   1.18	   1.49	   2.25	   1.84	  
Dguok	   20.01	   17.58	   17.85	   17.11	   17.63	   22.14	   19.03	   17.30	   16.17	  
Enpp1	   2.67	   2.69	   2.79	   3.47	   3.70	   2.06	   3.17	   3.88	   3.51	  
Enpp3	   9.65	   7.92	   7.88	   11.12	   11.64	   10.20	   9.79	   14.50	   16.15	  
Enpp4	   1.71	   1.40	   2.20	   2.33	   1.27	   1.53	   1.49	   1.83	   1.87	  
Entpd1	   1.67	   1.54	   1.32	   1.70	   1.88	   0.80	   1.34	   1.32	   1.50	  
Entpd2	   0.83	   0.80	   1.16	   1.22	   1.00	   0.95	   0.98	   0.86	   1.47	  
Entpd5	   34.53	   31.88	   36.86	   36.16	   33.40	   29.21	   40.80	   34.78	   41.17	  
Entpd6	   3.94	   4.39	   5.46	   4.32	   5.45	   5.14	   5.14	   4.50	   4.34	  
Entpd8	   46.11	   54.37	   53.62	   40.10	   38.75	   61.74	   42.00	   39.78	   35.77	  
Fhit	   9.18	   4.44	   5.96	   6.07	   4.61	   6.61	   8.97	   5.12	   10.83	  
Gart	   10.38	   12.55	   11.36	   9.77	   11.92	   9.91	   10.17	   11.41	   11.59	  
Gda	   7.73	   7.75	   7.82	   7.00	   7.42	   5.09	   7.22	   7.03	   7.30	  
Gmpr	   0.69	   0.31	   0.57	   0.48	   0.63	   0.38	   0.56	   0.37	   0.14	  
Gmpr2	   9.81	   10.64	   10.67	   11.10	   9.33	   9.15	   9.44	   9.00	   12.47	  
Gmps	   12.70	   11.26	   9.48	   14.79	   15.82	   9.41	   13.29	   16.35	   18.97	  
Gucy1a2	   0.16	   0.10	   0.12	   0.21	   0.13	   0.14	   0.14	   0.17	   0.21	  
Gucy2c	   0.08	   0.25	   0.12	   0.17	   0.35	   0.02	   0.15	   0.35	   0.31	  
Gucy2g	   0.07	   0.00	   0.01	   0.00	   0.00	   0.00	   0.00	   0.01	   0.00	  
Guk1	   25.12	   23.42	   25.83	   26.17	   24.01	   24.79	   28.40	   28.69	   27.99	  
Hddc3	   1.68	   3.81	   3.07	   1.44	   2.00	   2.48	   3.06	   0.97	   3.35	  
Hprt	   44.75	   41.47	   44.83	   46.54	   43.77	   38.14	   51.62	   47.73	   56.88	  
Impdh1	   0.82	   0.54	   0.67	   0.76	   0.88	   0.96	   0.87	   0.90	   0.47	  
Impdh2	   22.99	   21.01	   21.27	   22.53	   25.28	   21.30	   28.15	   26.33	   24.99	  
Itpa	   12.74	   11.10	   13.15	   10.87	   11.55	   7.81	   14.31	   14.23	   17.77	  
Nme1	   46.29	   41.25	   43.18	   47.68	   42.24	   51.53	   53.95	   51.55	   62.58	  
Nme2	   288	   273	   278	   248	   236	   340	   242	   248	   282	  
Nme3	   28.32	   28.11	   28.54	   21.73	   24.25	   30.66	   28.19	   22.69	   29.59	  
Nme4	   0.63	   1.65	   1.78	   0.96	   1.51	   1.56	   2.39	   1.20	   1.48	  
Nme6	   20.59	   16.74	   19.79	   23.74	   19.80	   27.11	   25.76	   27.52	   26.88	  
Nme7	   3.01	   2.32	   1.67	   3.85	   3.39	   1.70	   3.94	   5.16	   3.97	  
Npr1	   4.21	   4.99	   6.01	   5.20	   5.26	   4.95	   4.59	   3.68	   3.01	  
Npr2	   17.72	   21.29	   19.77	   20.56	   14.13	   24.30	   14.88	   18.35	   11.30	  
Nt5c	   23.98	   31.42	   22.08	   24.06	   33.60	   27.16	   24.84	   23.48	   28.07	  
Nt5c2	   4.13	   3.95	   4.24	   4.14	   3.65	   4.02	   3.87	   4.02	   3.28	  
Nt5c3	   12.14	   10.75	   11.98	   11.58	   12.71	   12.67	   14.02	   12.77	   14.58	  
Nt5c3b	   2.25	   2.04	   2.39	   2.63	   1.61	   1.47	   1.47	   1.72	   1.33	  
Nt5e	   13.65	   12.98	   11.44	   13.81	   15.99	   11.64	   15.45	   17.20	   18.35	  
Nt5m	   11.07	   11.18	   10.84	   9.06	   9.92	   12.01	   10.87	   9.11	   8.52	  
Ntpcr	   5.66	   5.87	   4.78	   4.51	   5.41	   4.95	   5.13	   4.96	   4.94	  




Nudt2	   21.39	   26.69	   27.90	   26.38	   17.73	   22.56	   19.79	   17.96	   28.36	  
Nudt5	   9.40	   6.38	   7.16	   10.82	   9.30	   9.79	   9.89	   10.82	   11.17	  
Nudt9	   33.74	   31.00	   38.45	   35.61	   37.74	   32.26	   37.64	   38.60	   38.39	  
Paics	   77.24	   70.56	   67.19	   75.44	   78.84	   71.02	   66.73	   59.81	   101.98	  
Papss1	   6.07	   4.97	   5.20	   5.59	   4.55	   5.41	   4.78	   6.94	   5.72	  
Papss2	   114	   137	   122	   111	   129	   79	   116	   86	   123	  
Pde10a	   0.06	   0.11	   0.10	   0.08	   0.10	   0.08	   0.07	   0.06	   0.03	  
Pde1a	   0.85	   0.87	   1.13	   1.39	   0.78	   0.41	   1.27	   0.44	   0.53	  
Pde1b	   0.83	   0.85	   1.08	   0.51	   0.71	   1.43	   0.45	   0.84	   0.65	  
Pde1c	   0.08	   0.10	   0.02	   0.08	   0.10	   0.19	   0.04	   0.07	   0.10	  
Pde2a	   4.29	   6.24	   6.02	   5.11	   4.74	   5.79	   5.28	   3.32	   2.47	  
Pde3a	   0.06	   0.00	   0.00	   0.17	   0.06	   0.11	   0.03	   0.22	   0.15	  
Pde3b	   23.59	   22.89	   21.05	   22.34	   25.52	   21.41	   21.06	   20.74	   27.71	  
Pde4a	   1.74	   1.52	   1.95	   1.71	   1.43	   2.28	   1.79	   1.50	   1.17	  
Pde4b	   7.46	   5.36	   5.16	   8.79	   7.49	   9.90	   4.85	   13.84	   10.26	  
Pde4c	   4.16	   4.05	   6.20	   2.89	   2.97	   7.58	   3.11	   3.66	   2.16	  
Pde4d	   0.78	   0.73	   0.91	   1.03	   0.56	   0.74	   0.80	   0.85	   0.54	  
Pde5a	   0.20	   0.36	   0.41	   0.51	   0.27	   0.24	   0.28	   0.23	   0.28	  
Pde6a	   0.01	   0.00	   0.00	   0.00	   0.00	   0.00	   0.02	   0.00	   0.00	  
Pde6c	   0.60	   0.52	   0.55	   0.62	   0.45	   0.22	   1.32	   0.09	   0.33	  
Pde6d	   8.98	   7.88	   11.59	   9.99	   7.92	   9.84	   10.81	   7.11	   8.06	  
Pde6g	   1.16	   1.09	   1.36	   0.56	   0.73	   0.78	   0.93	   0.48	   0.55	  
Pde7a	   1.74	   1.36	   1.52	   1.77	   1.61	   1.35	   1.56	   1.34	   1.66	  
Pde7b	   0.59	   0.36	   0.37	   0.83	   1.07	   0.37	   0.34	   0.55	   0.18	  
Pde8a	   9.49	   7.21	   6.27	   10.49	   12.43	   7.05	   7.51	   10.05	   8.43	  
Pde8b	   0.53	   0.72	   1.21	   0.68	   0.45	   1.05	   0.62	   0.62	   0.72	  
Pde9a	   21.54	   21.64	   19.00	   19.05	   19.11	   18.42	   16.22	   18.28	   22.80	  
Pfas	   2.40	   2.37	   1.98	   1.66	   1.98	   1.95	   2.59	   2.03	   1.38	  
Pgm1	   4.79	   3.93	   4.12	   4.70	   4.81	   4.00	   3.74	   3.87	   4.76	  
Pgm2	   77.20	   77.51	   76.15	   81.34	   88.26	   65.63	   94.33	   87.07	   101.04	  
Pklr	   126	   157	   186	   120	   273	   127	   133	   147	   222	  
Pkm	   5.59	   6.56	   6.51	   9.33	   6.73	   5.39	   5.76	   8.14	   6.12	  
Pnp	   29.12	   25.32	   25.66	   30.66	   30.16	   15.83	   30.06	   28.60	   36.92	  
Pnp2	   0.51	   0.32	   0.04	   0.23	   0.16	   0.17	   0.52	   0.11	   0.15	  
Pnpt1	   16.14	   13.81	   14.09	   15.48	   17.11	   12.11	   13.73	   16.97	   21.23	  
Pola1	   0.51	   0.45	   0.62	   0.41	   0.35	   0.48	   0.58	   0.57	   0.83	  
Pola2	   2.87	   2.88	   2.69	   3.45	   2.71	   2.90	   1.88	   2.23	   2.32	  
Pold1	   1.19	   1.27	   1.49	   1.60	   1.51	   1.31	   1.14	   1.07	   0.94	  
Pold2	   7.91	   8.28	   8.95	   8.03	   8.02	   8.51	   8.08	   9.09	   8.13	  
Pold3	   4.97	   3.81	   5.32	   5.23	   4.34	   5.38	   4.78	   4.79	   5.17	  
Pold4	   21.60	   32.24	   31.78	   19.70	   16.74	   29.39	   28.93	   19.34	   17.94	  
Pole	   0.32	   0.38	   0.35	   0.40	   0.20	   0.24	   0.12	   0.23	   0.13	  
Pole2	   0.35	   0.25	   0.20	   0.54	   0.06	   0.50	   0.14	   0.05	   0.47	  
Pole3	   27.09	   27.50	   22.54	   29.28	   26.76	   28.88	   22.81	   31.02	   27.96	  
Pole4	   10.55	   8.59	   10.51	   10.62	   9.52	   10.19	   11.61	   9.61	   10.13	  
Polr1a	   4.09	   4.74	   4.54	   4.75	   4.27	   4.67	   4.13	   4.91	   5.20	  
Polr1b	   5.18	   5.69	   4.62	   4.62	   6.58	   6.32	   5.83	   6.35	   5.36	  




Polr1d	   67.66	   64.91	   63.64	   65.65	   65.13	   57.66	   68.97	   70.85	   68.06	  
Polr1e	   1.30	   1.75	   2.17	   1.85	   2.39	   1.73	   2.71	   2.50	   3.19	  
Polr2a	   6.01	   7.87	   8.30	   8.18	   8.80	   7.78	   6.93	   7.72	   5.05	  
Polr2b	   6.88	   7.19	   5.20	   10.17	   9.20	   4.67	   7.71	   10.41	   11.85	  
Polr2c	   13.17	   12.14	   14.82	   12.61	   12.82	   15.65	   15.33	   15.33	   14.57	  
Polr2d	   6.60	   5.98	   9.35	   8.17	   8.45	   6.15	   6.85	   8.85	   8.68	  
Polr2e	   28.28	   33.51	   33.02	   27.85	   33.00	   34.38	   31.39	   30.24	   35.70	  
Polr2f	   90.82	   107.34	   115.10	   81.73	   78.27	   124.02	   85.07	   79.82	   97.97	  
Polr2g	   12.64	   11.91	   12.70	   12.45	   12.57	   8.90	   16.74	   16.55	   16.57	  
Polr2h	   11.07	   12.73	   10.13	   11.13	   11.82	   12.82	   17.14	   12.15	   17.18	  
Polr2i	   46.88	   43.17	   52.40	   43.42	   48.45	   54.69	   48.27	   45.30	   47.49	  
Polr2j	   95.29	   90.50	   98.10	   79.45	   82.01	   80.06	   72.25	   73.80	   82.93	  
Polr2l	   23.20	   25.96	   25.68	   19.44	   19.00	   26.86	   26.23	   18.98	   20.81	  
Polr3a	   4.44	   4.07	   4.49	   4.88	   4.06	   5.35	   4.10	   5.00	   4.68	  
Polr3b	   2.56	   2.69	   2.52	   3.08	   3.01	   2.70	   2.55	   2.61	   2.72	  
Polr3c	   12.47	   10.15	   10.96	   16.52	   12.36	   10.86	   14.64	   13.53	   11.51	  
Polr3d	   7.19	   8.97	   7.26	   9.05	   11.58	   8.99	   10.72	   12.79	   11.23	  
Polr3e	   4.06	   3.73	   3.09	   3.28	   3.86	   4.66	   4.63	   4.96	   5.35	  
Polr3f	   5.04	   4.96	   4.45	   4.42	   5.50	   5.14	   4.76	   5.13	   5.34	  
Polr3g	   4.11	   4.88	   5.38	   3.65	   4.06	   3.95	   3.77	   3.19	   3.58	  
Polr3gl	   16.30	   22.44	   16.23	   13.20	   19.17	   10.94	   19.54	   14.02	   14.38	  
Polr3h	   2.63	   2.64	   3.02	   2.32	   2.02	   2.96	   2.29	   2.82	   2.59	  
Polr3k	   6.93	   6.56	   6.04	   6.84	   6.37	   5.93	   5.56	   6.74	   7.62	  
Ppat	   7.83	   4.84	   5.58	   7.18	   7.44	   4.41	   5.89	   6.00	   7.77	  
Prim1	   3.50	   2.02	   4.94	   2.96	   2.75	   2.22	   2.22	   3.25	   2.93	  
Prim2	   1.24	   1.75	   1.21	   1.44	   1.66	   1.38	   1.03	   1.42	   1.41	  
Prps1	   12.43	   10.79	   12.30	   14.15	   15.54	   9.53	   15.47	   17.42	   18.48	  
Prps1l1	   0.10	   0.00	   0.09	   0.00	   0.00	   0.12	   0.00	   0.03	   0.00	  
Prps1l3	   8.59	   9.46	   7.25	   9.43	   11.41	   8.07	   9.56	   11.21	   15.61	  
Prps2	   6.04	   4.32	   5.70	   4.91	   5.72	   3.14	   5.09	   5.57	   5.63	  
Rrm1	   2.94	   2.40	   2.11	   3.33	   2.83	   1.89	   2.07	   2.80	   2.83	  
Rrm2	   3.45	   1.86	   2.80	   3.09	   6.04	   2.59	   3.23	   3.22	   4.68	  
Rrm2b	   1.00	   1.11	   0.83	   1.05	   1.04	   0.83	   0.59	   1.24	   0.59	  
Twistnb	   13.83	   12.47	   12.42	   10.80	   9.86	   17.25	   13.08	   10.59	   13.75	  
Uox	   787	   703	   767	   767	   935	   598	   715	   656	   1093	  
Urad	   14.35	   15.80	   13.20	   15.08	   14.67	   10.10	   14.61	   20.91	   19.00	  
Urah	   354.77	   362.98	   380.07	   356.94	   363.75	   330.83	   421.90	   384.78	   397.00	  
Xdh	   30.48	   35.96	   28.77	   28.34	   38.51	   30.28	   27.43	   32.88	   29.16	  
Znrd1	   36.74	   29.27	   43.88	   38.27	   41.10	   49.28	   48.55	   33.68	   43.97	  
 
Purine	  Transcriptomic	  analysis	  in	  female	  mice	  livers	  
Sample	   1	   2	   3	   4	   5	   1	   2	   3	   4	   5	  
Phenotype	   ERD	   ERD	   ERD	   ERD	   ERD	   ERS	   ERS	   ERS	   ERS	   ERS	  
miRNA	   FPKM	  
mmu-­‐miR-­‐106a-­‐5p	   0	   0.12	   0	   0	   0	   0.27	   0.26	   0.18	   0.34	   0	  
mmu-­‐miR-­‐1945	   0	   0.18	   0.19	   0.25	   0.33	   0.53	   0.6	   0.5	   0.25	   0.5	  




mmu-­‐miR-­‐377-­‐3p	   0	   0	   0	   0	   0.05	   0	   0.09	   0.14	   0.15	   0.21	  
mmu-­‐miR-­‐8098	   0	   0.06	   0	   0	   0	   0.16	   0.17	   0.05	   0.1	   0	  
mmu-­‐miR-­‐344-­‐3p	   0.07	   0.06	   0	   0.08	   0.05	   0	   0	   0	   0.02	   0	  
mmu-­‐miR-­‐5709-­‐5p	   0.07	   0	   0.19	   0	   0	   0.53	   0.26	   0.23	   0	   0.28	  
mmu-­‐miR-­‐7236-­‐3p	   0.07	   0.67	   0.77	   0.25	   0.11	   1.87	   0.69	   1.05	   0.49	   0.92	  
mmu-­‐miR-­‐877-­‐3p	   0.07	   0	   0.05	   0	   0	   0.11	   0.09	   0.23	   0.05	   0.14	  
mmu-­‐miR-­‐669d-­‐5p	   0.14	   0.09	   0	   0.12	   0.16	   0.05	   0	   0.07	   0	   0	  
mmu-­‐miR-­‐7072-­‐5p	   0.14	   0	   0	   0.17	   0	   0.32	   0.09	   0.23	   0.29	   0.21	  
mmu-­‐miR-­‐187-­‐5p	   0.29	   0.18	   0.14	   0.33	   0.22	   0.59	   0.86	   0.46	   0.78	   0.14	  
mmu-­‐miR-­‐328-­‐5p	   0.29	   0.12	   0	   0.17	   0.16	   0.32	   0.17	   0.37	   0.39	   0.28	  
mmu-­‐miR-­‐376c-­‐3p	   0.29	   0.55	   0.24	   0.92	   0.71	   0.11	   0	   0	   0.05	   0	  
mmu-­‐miR-­‐6911-­‐3p	   0.6	   0.7	   1.1	   0.8	   1.2	   0.5	   0.6	   0.4	   0.2	   0.6	  
mmu-­‐miR-­‐29c-­‐5p	   1.6	   1.7	   1.7	   1.7	   1.8	   1.8	   1.7	   2.1	   1.8	   2.2	  
mmu-­‐miR-­‐6516-­‐5p	   1.7	   1.2	   1.6	   2.0	   1.5	   2.2	   2.5	   2.1	   2.5	   1.6	  
mmu-­‐miR-­‐193b-­‐3p	   2.2	   2.4	   1.9	   1.8	   2.5	   1.7	   1.2	   1.4	   1.2	   1.1	  
mmu-­‐miR-­‐378b	   2.7	   3.8	   3.3	   1.7	   4.7	   1.6	   2.4	   2.0	   1.6	   2.3	  
mmu-­‐miR-­‐338-­‐5p	   3.3	   2.6	   2.6	   3.2	   2.7	   2.1	   1.8	   2.4	   1.3	   2.1	  
mmu-­‐miR-­‐1191a	   3.5	   3.0	   2.7	   1.8	   1.4	   4.5	   2.9	   5.3	   3.2	   3.8	  
mmu-­‐miR-­‐96-­‐5p	   3.5	   4.1	   2.0	   3.6	   2.5	   5.4	   4.4	   4.2	   3.6	   3.9	  
mmu-­‐miR-­‐192-­‐3p	   4.8	   5.9	   5.6	   6.2	   4.5	   6.6	   5.9	   6.9	   6.0	   7.7	  
mmu-­‐miR-­‐342-­‐5p	   7.5	   7.3	   7.8	   7.7	   8.0	   8.5	   8.1	   9.1	   9.9	   9.1	  
mmu-­‐miR-­‐221-­‐5p	   10	   8	   8	   10	   9	   17	   13	   14	   15	   15	  
mmu-­‐miR-­‐362-­‐3p	   11	   9	   9	   5	   5	   17	   21	   15	   10	   8	  
mmu-­‐miR-­‐322-­‐3p	   14	   14	   15	   16	   15	   18	   21	   22	   21	   18	  
mmu-­‐miR-­‐582-­‐3p	   14	   16	   12	   17	   14	   17	   15	   17	   18	   18	  
mmu-­‐miR-­‐501-­‐3p	   21	   20	   18	   26	   28	   40	   36	   45	   39	   36	  
mmu-­‐miR-­‐340-­‐3p	   21	   18	   19	   19	   19	   21	   24	   22	   22	   21	  
mmu-­‐miR-­‐374b-­‐5p	   21	   20	   20	   20	   20	   20	   22	   25	   23	   22	  
mmu-­‐miR-­‐335-­‐3p	   24	   28	   24	   19	   20	   26	   29	   33	   30	   29	  
mmu-­‐miR-­‐674-­‐3p	   26	   21	   26	   31	   18	   29	   36	   41	   32	   34	  
mmu-­‐miR-­‐421-­‐3p	   33	   32	   34	   28	   30	   34	   36	   37	   36	   37	  
mmu-­‐miR-­‐335-­‐5p	   33	   28	   32	   33	   33	   30	   43	   41	   41	   39	  
mmu-­‐miR-­‐17-­‐5p	   37	   36	   33	   30	   36	   44	   46	   43	   37	   36	  
mmu-­‐miR-­‐322-­‐5p	   37	   37	   35	   38	   38	   40	   46	   42	   36	   41	  
mmu-­‐miR-­‐1948-­‐3p	   59	   49	   55	   69	   54	   74	   84	   98	   82	   88	  
mmu-­‐miR-­‐142a-­‐3p	   60	   56	   65	   54	   48	   71	   63	   75	   72	   64	  
mmu-­‐miR-­‐145a-­‐3p	   81	   131	   106	   76	   90	   118	   140	   128	   118	   123	  
mmu-­‐miR-­‐148b-­‐3p	   83	   76	   81	   81	   72	   106	   100	   98	   90	   97	  
mmu-­‐miR-­‐146b-­‐5p	   100	   130	   116	   121	   133	   106	   94	   94	   92	   105	  
mmu-­‐miR-­‐671-­‐3p	   169	   141	   142	   166	   119	   175	   150	   193	   193	   183	  
mmu-­‐miR-­‐1843b-­‐5p	   196	   201	   212	   211	   190	   218	   207	   241	   218	   221	  
mmu-­‐miR-­‐28a-­‐5p	   206	   197	   203	   189	   160	   209	   234	   219	   216	   207	  
mmu-­‐miR-­‐29c-­‐3p	   248	   216	   223	   212	   183	   250	   291	   277	   255	   227	  
mmu-­‐miR-­‐100-­‐5p	   314	   431	   326	   362	   424	   520	   504	   601	   541	   561	  
mmu-­‐miR-­‐1843a-­‐5p	   483	   485	   506	   502	   458	   531	   519	   571	   523	   554	  
mmu-­‐miR-­‐103-­‐3p	   585	   516	   540	   504	   476	   741	   824	   662	   635	   579	  
mmu-­‐miR-­‐107-­‐3p	   779	   675	   742	   731	   579	   987	   1062	   835	   857	   852	  




mmu-­‐miR-­‐99b-­‐5p	   1031	   1381	   1067	   1294	   1399	   1641	   1643	   1992	   1882	   1711	  
mmu-­‐miR-­‐340-­‐5p	   1167	   991	   1105	   1034	   953	   1302	   1342	   1185	   1184	   1099	  
mmu-­‐miR-­‐125a-­‐5p	   1904	   2423	   1988	   1994	   2355	   2541	   2181	   2552	   2804	   2401	  
mmu-­‐miR-­‐26b-­‐5p	   2009	   2001	   1924	   1911	   1798	   1976	   2330	   2304	   2179	   2036	  
mmu-­‐miR-­‐194-­‐5p	   2059	   1923	   1789	   2016	   1459	   1959	   2081	   2214	   2230	   2123	  
mmu-­‐miR-­‐423-­‐5p	   2088	   1651	   1970	   2114	   2046	   2349	   2197	   2400	   2603	   2202	  
 
Urine	  purine	  metabolites	  in	  DA	  vs	  DC	  
Sample	   1	   2	   3	   4	   1	   2	   3	  
Phenotype	   DA	   DA	   DA	   DA	   DC	   DC	   DC	  
Metabolites	   Peak	  Intensities	  (10^4)	  
Gly	   12.6	   22.6	   18.4	   5.17	   10	   14.2	   1.61	  
Ser	   219	   283	   106	   68	   315	   187	   72.7	  
cystathione	   30	   80.6	   58.1	   97.5	   15.5	   27.1	   44.3	  
Adenine	   4.2	   13800	   3.88	   7.59	   4.52	   3.56	   16	  
guanine	   19100	   17900	   12300	   11600	   11000	   12700	   16100	  
Guanosine	   152	   310	   256	   175	   437	   236	   169	  
Adenosine	   77600	   72200	   47600	   43600	   44100	   52800	   61100	  
AICAR	   10.8	   76.9	   158	   7.75	   24.9	   27.1	   16.5	  
IMP	   101	   217	   150	   62.7	   131	   122	   28.1	  
XMP	   4.52	   19.7	   4.2	   2.26	   10.7	   5.81	   3.23	  
GMP	   31.3	   40.4	   17.1	   10.7	   9.37	   21.5	   4.52	  
AMP	   172	   217	   199	   133	   136	   121	   110	  
Inosine	   1480	   938	   596	   1690	   1510	   2420	   878	  
hypoxanthine	   14100	   5630	   7310	   10000	   13700	   18400	   13100	  
Xanthine	   51600	   24000	   25600	   118000	   128000	   150000	   50300	  
Uric	  Acid	   51500	   65400	   27700	   12900	   40300	   13500	   3850	  
Glu-­‐6-­‐P	   243	   310	   160	   48.3	   58.8	   62.3	   11.5	  
Fru-­‐6-­‐P	   22.3	   52.3	   19.4	   0.807	   5.81	   2.26	   4.2	  
Fru-­‐1,6-­‐biP	   161	   653	   117	   138	   130	   46.7	   76.1	  
6-­‐P-­‐Gluconate	   44.6	   6.46	   193	   5.49	   14.5	   34.7	   8.08	  
PRPP	   0.646	   0	   3.55	   0.969	   170	   270	   1.62	  
xanthosine	   7190	   5940	   3640	   1890	   5120	   2360	   552	  
GDP	   2.58	   5.81	   3.88	   0.323	   5.82	   2.91	   3.55	  
GTP	   6.14	   13.2	   7.11	   2.91	   2.58	   3.23	   2.58	  
ADP	   0.646	   5.81	   4.52	   1.94	   3.88	   1.94	   2.26	  
ATP	   0.969	   0.323	   0.645	   0.323	   0.323	   1.61	   0.646	  
cAMP	   217	   401	   432	   607	   1830	   1460	   797	  
Allantoin	   9.04	   21	   21.5	   11.6	   7.91	   5.98	   7.75	  
FMN	   32.3	   252	   145	   142	   40.4	   43.6	   63	  
 
Plasma	  purine	  metabolites	  in	  DA	  vs	  DC	  
Sample	   1	   2	   3	   4	   1	   2	   3	   4	  
Phenotype	   DA	   DA	   DA	   DA	   DC	   DC	   DC	   DC	  
Metabolites	   Peak	  Intensities	   	  	  




guanine	   1490000	   1120000	   4100000	   7520000	   1180000	   3360000	   1410000	   3620000	  
Guanosine	   19400	   47500	   22100	   122000	   104000	   9210	   129000	   8720	  
Adenosine	   5230000	   4070000	   14400000	   26700000	   4450000	   12300000	   4940000	   12400000	  
AICAR	   23600	   11600	   22000	   21000	   13200	   11100	   30200	   19900	  
IMP	   40400	   31300	   20400	   54600	   28400	   28400	   17800	   13600	  
XMP	   323	   646	   969	   4520	   1940	   646	   646	   969	  
GMP	   7110	   13900	   12900	   9040	   7110	   7430	   6460	   5490	  
AMP	   230000	   205000	   212000	   144000	   185000	   185000	   183000	   182000	  
FAD	   5490	   2910	   5810	   7750	   3230	   1940	   3880	   645	  
Inosine	   234000	   206000	   336000	   398000	   440000	   735000	   347000	   646000	  
hypoxanthine	   1320000	   880000	   1720000	   1340000	   2020000	   2450000	   1660000	   1140000	  
Xanthine	   1240000	   848000	   897000	   1370000	   1640000	   1480000	   1280000	   1400000	  
Uric	  Acid	   5460000	   4330000	   4770000	   4550000	   1560000	   6460000	   4870000	   24700000	  
Glu-­‐6-­‐P	   7750	   1940	   1940	   4850	   3880	   1450	   2910	   2260	  
Fru-­‐1,6-­‐biP	   145000	   40200	   62700	   33800	   29700	   44900	   22100	   33600	  
PRPP	   1610	   646	   3550	   2260	   2910	   323	   7110	   1940	  
xanthosine	   12000	   3230	   7750	   2910	   808	   15200	   16300	   33300	  
GDP	   323	   323	   645	   323	   1290	   323	   323	   323	  
GTP	   646	   323	   646	   2580	   1610	   1610	   968	   323	  
ADP	   323	   968	   646	   323	   969	   323	   0	   0	  
ATP	   969	   647	   1290	   646	   969	   323	   646	   1940	  
cAMP	   7750	   15800	   11900	   11300	   4520	   18100	   8080	   25200	  
Allantoin	   323	   969	   323	   645	   1290	   646	   323	   969	  
FMN	   647	   323	   2260	   2260	   646	   1290	   1290	   323	  
 
 




type	   Ala	   Arg	   Asn	   Asp	   Cys	   Gln	   Glu	  
1	   SF	   218000	   87400	   17000	   108000	   112000	   1320000	   182000	  
2	   SF	   3800000	   146000	   37800	   90100	   211000	   5100000	   233000	  
3	   SF	   3160000	   107000	   11600	   127000	   138000	   2190000	   253000	  
4	   SF	   2440000	   238000	   120000	   131000	   203000	   3650000	   253000	  
5	   SF	   4620000	   90100	   13400	   92200	   122000	   2550000	   265000	  
6	   SF	   15500000	   516000	   214000	   94500	   368000	   7000000	   491000	  
7	   SF	   7580000	   172000	   83000	   129000	   262000	   6670000	   535000	  
1	   HM	   1380000	   91600	   12600	   136000	   63000	   10300000	   86100	  
2	   HM	   474000	   316000	   97300	   107000	   448000	   14000000	   311000	  
3	   HM	   3410000	   134000	   49400	   108000	   455000	   20700000	   393000	  
4	   HM	   1600000	   159000	   42500	   131000	   191000	   33600000	   422000	  
5	   HM	   859000	   182000	   54600	   106000	   212000	   17800000	   442000	  
6	   HM	   1880000	   255000	   74200	   134000	   224000	   16500000	   468000	  
7	   HM	   7000000	   750000	   307000	   233000	   879000	   74100000	   572000	  
1	   CF	   2200000	   53600	   16800	   107000	   141000	   4780000	   143000	  
2	   CF	   9450000	   83400	   24600	   113000	   247000	   3490000	   150000	  




4	   CF	   7060000	   130000	   9690	   85600	   125000	   7980000	   166000	  
5	   CF	   9210000	   233000	   63300	   119000	   604000	   12000000	   207000	  
6	   CF	   597000	   50600	   15200	   110000	   273000	   4550000	   231000	  




type	   Gly	   His	   Ile	   Lys	   Met	   Phe	   Pro	  
1	   SF	   1290	   2610000	   40100000	   169000	   2380000	   15100000	   1330000	  
2	   SF	   7750	   7350000	   40100000	   129000	   3120000	   19000000	   3530000	  
3	   SF	   2260	   2920000	   40000000	   131000	   3580000	   14900000	   3090000	  
4	   SF	   5810	   16600000	   67600000	   145000	   2630000	   34600000	   1020000	  
5	   SF	   3230	   3280000	   42100000	   150000	   3080000	   21200000	   1970000	  
6	   SF	   27100	   26200000	   35500000	   132000	   2120000	   28900000	   11900000	  
7	   SF	   7430	   9310000	   29800000	   235000	   1520000	   18200000	   5120000	  
1	   HM	   2580	   2250000	   48600000	   132000	   3430000	   18300000	   1930000	  
2	   HM	   6140	   18400000	   74500000	   85100	   4260000	   26700000	   4090000	  
3	   HM	   15800	   11300000	   40400000	   369000	   2980000	   26200000	   12100000	  
4	   HM	   3230	   6880000	   34900000	   253000	   2860000	   20800000	   9380000	  
5	   HM	   11000	   10900000	   55000000	   188000	   2910000	   26800000	   9890000	  
6	   HM	   12600	   16400000	   43700000	   95300	   3220000	   27900000	   6760000	  
7	   HM	   30400	   89100000	   67700000	   9040	   5240000	   38900000	   20300000	  
1	   CF	   1290	   1940000	   23800000	   160000	   2020000	   9940000	   1500000	  
2	   CF	   8070	   3410000	   42200000	   138000	   2760000	   18000000	   5280000	  
3	   CF	   16200	   2160000	   53000000	   260000	   3810000	   24200000	   13600000	  
4	   CF	   5170	   1870000	   35300000	   175000	   2330000	   23400000	   7570000	  
5	   CF	   12900	   11900000	   50500000	   128000	   2260000	   34400000	   3230000	  
6	   CF	   4850	   3310000	   36000000	   146000	   2990000	   23500000	   2610000	  




type	   Ser	   Thr	   Trp	   Tyr	   Val	   Adenine	   guanine	  
1	   SF	   57100	   123000	   3670000	   633000	   30400	   28300	   16500000	  
2	   SF	   112000	   443000	   7280000	   1650000	   64000	   0	   24400000	  
3	   SF	   108000	   171000	   5140000	   791000	   39400	   408000	   22500000	  
4	   SF	   192000	   567000	   6930000	   2650000	   68500	   219000	   14800000	  
5	   SF	   29200	   139000	   9940000	   758000	   74300	   0	   23800000	  
6	   SF	   721000	   2210000	   19100000	   3500000	   72500	   1280000	   26100000	  
7	   SF	   230000	   848000	   11200000	   1580000	   82200	   1340000	   35200000	  
1	   HM	   136000	   155000	   2160000	   763000	   50100	   818000	   29700000	  
2	   HM	   586000	   571000	   9100000	   2030000	   82100	   606000	   36000000	  
3	   HM	   438000	   1040000	   27200000	   1560000	   110000	   3120000	   32700000	  
4	   HM	   386000	   482000	   25600000	   2000000	   83400	   1790000	   36300000	  
5	   HM	   407000	   823000	   20700000	   2450000	   77900	   6010000	   54900000	  
6	   HM	   507000	   608000	   14600000	   2520000	   120000	   804000	   44900000	  
7	   HM	   3150000	   2370000	   53300000	   6150000	   166000	   2690000	   8800000	  
1	   CF	   125000	   134000	   3900000	   420000	   65900	   458000	   24900000	  
2	   CF	   69800	   318000	   12200000	   1330000	   151000	   527000	   11400000	  
3	   CF	   61400	   299000	   17800000	   1270000	   180000	   1270000	   37900000	  
4	   CF	   3880	   308000	   13000000	   1080000	   168000	   1380000	   21400000	  
5	   CF	   242000	   722000	   19200000	   2010000	   191000	   21400000	   25100000	  














A_pos	   AICAR	   IMP	   XMP	  
1	   SF	   88200	   65000000	   141000	   15500	   32600	   46500	   2260	  
2	   SF	   107000	   76800000	   2130	   12600	   20500	   38900	   1940	  
3	   SF	   75600	   72300000	   8720	   2910	   53900	   28800	   969	  
4	   SF	   123000	   65200000	   31600	   3230	   43000	   68500	   4520	  
5	   SF	   114000	   77400000	   9880	   24900	   21300	   37000	   323	  
6	   SF	   132000	   64500000	   5620	   14200	   51700	   71100	   1940	  
7	   SF	   172000	  
11900000
0	   8720	   12000	   4310000	   112000	   4840	  
1	   HM	   491000	  
10700000
0	   19800	   19700	   39500	   34600	   645	  
2	   HM	   171000	  
12700000
0	   7750	   20000	   41500	   42300	   1940	  
3	   HM	   167000	  
12400000
0	   15900	   24900	   45700	   30700	   1940	  
4	   HM	   168000	  
14700000
0	   13600	   21300	   32900	   57200	   969	  
5	   HM	   162000	  
21800000
0	   51900	   43000	   26200	   68300	   2910	  
6	   HM	   143000	  
15300000
0	   9300	   29700	   37500	   53900	   2910	  
7	   HM	   327000	   33100000	   58700	   12000	   48300	   134000	   4840	  
1	   CF	   110000	   97300000	   9880	   8080	   12600	   70400	   2580	  
2	   CF	   120000	   35800000	   10700	   20000	   86900	   36800	   4850	  
3	   CF	   136000	  
13000000
0	   2910	   23600	   26800	   57300	   4840	  
4	   CF	   146000	   74800000	   2330	   25200	   77100	   37500	   2580	  
5	   CF	   122000	   86800000	   8140	   19400	   37600	   50400	   2260	  
6	   CF	   107000	  
13400000
0	   10100	   6780	   53500	   32600	   323	  
7	   CF	   168000	  
10400000




type	   GMP	   AMP	   Urea	  
hydroxypro
line	   GSHpos	   GSSGpos	   NADpos	  
1	   SF	   7100	   230000	   231000000	   297000	   22600	   113000	   2580	  
2	   SF	   18100	   213000	   116000000	   704000	   57200	   115000	   2260	  
3	   SF	   7750	   235000	   128000000	   1380000	   28400	   134000	   1620	  
4	   SF	   22500	   231000	   187000000	   351000	   67500	   148000	   969	  
5	   SF	   12600	   328000	   170000000	   493000	   42200	   103000	   1290	  
6	   SF	   27600	   328000	   112000000	   4540000	   39100	   112000	   22300	  
7	   SF	   18400	   420000	   149000000	   1660000	   83000	   71700	   33300	  
1	   HM	   9370	   234000	   71800000	   422000	   19400	   72400	   969	  
2	   HM	   23300	   184000	   167000000	   1300000	   52700	   132000	   5170	  
3	   HM	   19100	   175000	   83200000	   3870000	   23600	   69500	   646	  
4	   HM	   13600	   188000	   127000000	   1670000	   24900	   56900	   646	  
5	   HM	   16100	   251000	   148000000	   1800000	   36800	   63300	   1290	  
6	   HM	   18900	   192000	   106000000	   2130000	   45200	   131000	   646	  
7	   HM	   28100	   226000	   116000000	   7830000	   63600	   78800	   1290	  




2	   CF	   6780	   141000	   99800000	   750000	   23900	   163000	   969	  
3	   CF	   11000	   147000	   134000000	   961000	   28800	   120000	   3550	  
4	   CF	   10300	   173000	   146000000	   506000	   22300	   136000	   1610	  
5	   CF	   16100	   140000	   107000000	   988000	   58000	   149000	   2260	  
6	   CF	   12000	   167000	   157000000	   1040000	   19400	   132000	   323	  








CoApos	   MalCoApos	  
Ethanolami
ne	  
1	   SF	   3550	   20000	   157000	   74600	   8720	   11600	   3490000	  
2	   SF	   2260	   67800	   168000	   97900	   7110	   47500	   1740000	  
3	   SF	   1940	   73300	   56100	   98200	   2580	   19700	   2440000	  
4	   SF	   5810	   23400	   167000	   41400	   14900	   15800	   2280000	  
5	   SF	   646	   50400	   136000	   83000	   3230	   13200	   6990000	  
6	   SF	   3230	   46500	   119000	   46700	   59100	   22600	   27400000	  
7	   SF	   77500	   71700	   116000	   64300	   26200	   26500	   16300000	  
1	   HM	   1620	   65300	   9040	   53000	   17000	   49700	   4590000	  
2	   HM	   1290	   52000	   76900	   255000	   21300	   25800	   3770000	  
3	   HM	   323	   72700	   5170	   112000	   26200	   69100	   3420000	  
4	   HM	   1290	   99200	   9690	   131000	   10700	   86600	   3440000	  
5	   HM	   2580	   74600	   27800	   88800	   1620	   30400	   3220000	  
6	   HM	   969	   87900	   10300	   142000	   1940	   72000	   3400000	  
7	   HM	   1940	   43900	   28700	   51200	   4200	   1610	   4480000	  
1	   CF	   2580	   43600	   52800	   48000	   40000	   27100	   4290000	  
2	   CF	   2910	   45500	   9040	   67200	   3230	   39400	   4960000	  
3	   CF	   3550	   83400	   11000	   43900	   3880	   72700	   1810000	  
4	   CF	   1940	   89200	   11600	   38800	   11600	   32900	   3230000	  
5	   CF	   969	   56900	   16200	   73300	   1620	   31700	   4300000	  
6	   CF	   645	   50400	   24900	   78800	   2260	   73700	   14100000	  




type	   Choline	   Creatine	   Nicotinimide	   Ornithine	   Citrulline	   Carnitine	  
phosphrylc
holine	  
1	   SF	   786000000	   4520	   47500000	   337000	   297000	   515000	   6980000	  
2	   SF	   274000000	   1940	   127000000	   421000	   1010000	   16700000	   5130000	  
3	   SF	   370000000	   1610	   156000000	   423000	   754000	   15200000	   4530000	  
4	   SF	   784000000	   7110	   38300000	   328000	   1330000	   6990000	   2590000	  
5	   SF	   514000000	   2580	   97800000	   313000	   419000	   2840000	   5900000	  
6	   SF	   390000000	   12000	   207000000	   476000	   1650000	   69500000	   9230000	  
7	   SF	   305000000	   88900	   107000000	   340000	   3750000	   27200000	   4350000	  
1	   HM	   640000000	   4840	   53300000	   427000	   5470000	   8800000	   6860000	  
2	   HM	   653000000	   2260	   46600000	   546000	   1410000	   2840000	   5620000	  
3	   HM	   372000000	   8400	   124000000	   588000	   2050000	   27700000	   10800000	  
4	   HM	   766000000	   2260	   40800000	   581000	   3100000	   4880000	   8510000	  
5	   HM	   431000000	   5170	   68700000	   503000	   3960000	   4950000	   11600000	  
6	   HM	   1.25E+09	   4850	   109000000	   511000	   1540000	   9800000	   12300000	  
7	   HM	   550000000	   2910	   81700000	   684000	   4960000	   37600000	   9820000	  
1	   CF	   673000000	   2260	   119000000	   313000	   532000	   14100000	   4590000	  
2	   CF	   1.01E+09	   1940	   67700000	   380000	   515000	   34100000	   5660000	  
3	   CF	   848000000	   2580	   55200000	   411000	   2230000	   49900000	   5480000	  




5	   CF	   480000000	   1940	   34600000	   342000	   414000	   68700000	   6130000	  
6	   CF	   575000000	   969	   86400000	   440000	   966000	   3890000	   7040000	  










hocholine	   thiamine	  
thiamine	  
posphate	   riboflavin	   FAD	  
1	   SF	   6630000	   20700	   24400	   397000000	   6460	   172000000	   3230	  
2	   SF	   221000000	   37500	   108000	   1.18E+09	   12300	   86300000	   0	  
3	   SF	   145000000	   4840	   84300	   528000000	   5490	   104000000	   1940	  
4	   SF	   85500000	   9690	   72400	   238000000	   18400	   175000000	   1290	  
5	   SF	   45500000	   27500	   64600	   768000000	   10000	   10800000	   647	  
6	   SF	   176000000	   66900	   334000	   417000000	   28100	   83100000	   323	  
7	   SF	   162000000	   1030000	   106000	   188000000	   58500	   88900000	   2910	  
1	   HM	   104000000	   7110	   38400	   2570000	   22000	   19200000	   2580	  
2	   HM	   27300000	   2590	   191000	   5140000	   17100	   20300000	   969	  
3	   HM	   65100000	   59600	   215000	   6220000	   25800	   9260000	   1940	  
4	   HM	   26900000	   14900	   92400	   24800000	   10000	   26200000	   969	  
5	   HM	   26900000	   28400	   56800	   11000000	   31300	   18800000	   2580	  
6	   HM	   37100000	   26500	   116000	   18000000	   5490	   107000000	   969	  
7	   HM	   40200000	   7910	   170000	   4660000	   24900	   8910000	   0	  
1	   CF	   266000000	   55600	   47800	   71900000	   27100	   168000000	   0	  
2	   CF	   315000000	   33600	   134000	   255000000	   12900	   112000000	   2910	  
3	   CF	   153000000	   51400	   109000	   104000000	   22900	   115000000	   969	  
4	   CF	   232000000	   6950	   84200	   102000000	   11900	   133000000	   1620	  
5	   CF	   415000000	   18900	   337000	   189000000	   19100	   166000000	   1290	  
6	   CF	   35300000	   33300	   83700	   409000000	   14500	   204000000	   1620	  




type	   3pSer	   SAM	   SAH_pos	   Inosine	  
hypoxanthi
ne	   Xanthine	   Uric	  Acid	  
1	   SF	   92400	   71400	   2260	   3600000	   18400000	   11700000	   25900000	  
2	   SF	   48500	   225000	   10500	   6190000	   28200000	   18700000	   37400000	  
3	   SF	   54300	   124000	   3230	   4150000	   43400000	   20000000	   30000000	  
4	   SF	   26200	   125000	   6780	   3410000	   16000000	   19500000	   27600000	  
5	   SF	   33600	   70400	   2260	   4610000	   29800000	   11300000	   28500000	  
6	   SF	   22300	   14900	   12300	   11000000	   45200000	   44500000	   49600000	  
7	   SF	   97200	   122000	   65300	   4790000	   37000000	   63000000	   38100000	  
1	   HM	   57800	   19100	   7270	   12300000	   55000000	   35700000	   16600000	  
2	   HM	   33300	   158000	   6300	   8670000	   28800000	   62000000	   45500000	  
3	   HM	   29400	   274000	   5820	   12300000	   99500000	   71600000	   29300000	  
4	   HM	   12000	   110000	   13200	   11400000	   91600000	   66700000	   31700000	  
5	   HM	   26500	   82100	   9040	   7990000	   51900000	   71300000	   37800000	  
6	   HM	   37800	   179000	   11600	   7450000	   37400000	   51000000	   42700000	  
7	   HM	   11000	   430000	   7430	   27500000	   157000000	   116000000	   20300000	  
1	   CF	   52000	   70400	   5170	   3640000	   34400000	   21900000	   24300000	  
2	   CF	   14900	   146000	   3550	   3350000	   36800000	   19300000	   31700000	  
3	   CF	   16800	   43300	   5490	   8720000	   73400000	   20600000	   13000000	  
4	   CF	   73000	   73300	   5810	   3790000	   55300000	   19100000	   20300000	  
5	   CF	   37800	   345000	   2260	   6940000	   34300000	   38400000	   46200000	  
6	   CF	   37800	   59400	   3550	   4950000	   38900000	   28200000	   19600000	  







type	   Glu-­‐6-­‐P	   Fru-­‐6-­‐P	   Fru-­‐1,6-­‐biP	   DHAP	   G-­‐3-­‐P	  
bisphospho
glycerate	   3-­‐P-­‐G	  
1	   SF	   13200	   4200	   187000	   325000	   194000	   26700	   341000	  
2	   SF	   18400	   6620	   203000	   471000	   323000	   27800	   445000	  
3	   SF	   27100	   7110	   298000	   613000	   281000	   6300	   447000	  
4	   SF	   19400	   5330	   594000	   1070000	   444000	   11600	   290000	  
5	   SF	   13200	   5650	   173000	   317000	   151000	   9370	   279000	  
6	   SF	   28400	   6940	   782000	   632000	   625000	   33300	   199000	  
7	   SF	   29200	   7750	   873000	   1390000	   1710000	   44300	   67100	  
1	   HM	   12100	   1450	   151000	   43800	   167000	   1610	   162000	  
2	   HM	   36200	   5490	   124000	   47200	   273000	   9370	   295000	  
3	   HM	   54900	   4040	   76900	   149000	   229000	   2260	   149000	  
4	   HM	   79800	   1450	   225000	   27000	   138000	   969	   97600	  
5	   HM	   119000	   2910	   289000	   51400	   432000	   1620	   67600	  
6	   HM	   28900	   1940	   325000	   108000	   179000	   2910	   195000	  
7	   HM	   223000	   7430	   266000	   2260	   358000	   2910	   145000	  
1	   CF	   18700	   5490	   128000	   2100	   190000	   13200	   384000	  
2	   CF	   14900	   5820	   146000	   4840	   244000	   42000	   317000	  
3	   CF	   12600	   1620	   194000	   1290	   118000	   1290	   41700	  
4	   CF	   12900	   4040	   70400	   14200	   307000	   33400	   126000	  
5	   CF	   15500	   6460	   166000	   1940	   249000	   59400	   269000	  
6	   CF	   7590	   4850	   98000	   7920	   106000	   3880	   601000	  











Gluconate	   Ribose-­‐5-­‐P	  
sedoheptul
ose-­‐7-­‐P	  
1	   SF	   559000	   197000	   646	   582000	   3230	   46000	   13000000	  
2	   SF	   936000	   196000	   646	   720000	   3230	   102000	   9110000	  
3	   SF	   540000	   224000	   969	   781000	   11300	   16200	   19100000	  
4	   SF	   415000	   371000	   647	   819000	   4200	   52600	   5120000	  
5	   SF	   633000	   199000	   15500	   722000	   68200	   79000	   5740000	  
6	   SF	   1540000	   443000	   3230	   1530000	   148000	   108000	   11400000	  
7	   SF	   1910000	   229000	   4200	   2250000	   247000	   50700	   7550000	  
1	   HM	   780000	   188000	   4200	   1410000	   7110	   1940	   26500000	  
2	   HM	   1570000	   369000	   968	   1120000	   10200	   49400	   28400000	  
3	   HM	   4050000	   404000	   646	   1040000	   3880	   46400	   40100000	  
4	   HM	   1800000	   170000	   2910	   1090000	   7110	   21600	   30400000	  
5	   HM	   2550000	   181000	   1290	   1030000	   9050	   49900	   44800000	  
6	   HM	   1510000	   512000	   323	   925000	   2100	   26800	   11600000	  
7	   HM	   3050000	   347000	   4840	   2860000	   4850	   147000	   95000000	  
1	   CF	   2070000	   306000	   646	   1060000	   67200	   4200	   23800000	  
2	   CF	   2470000	   338000	   323	   0	   65900	   24400	   12600000	  
3	   CF	   186000	   91700	   969	   290000	   1940	   1290	   31900000	  
4	   CF	   1220000	   108000	   646	   643000	   100000	   3880	   26100000	  
5	   CF	   2240000	   274000	   323	   757000	   64100	   27500	   6820000	  
6	   CF	   1560000	   211000	   1620	   669000	   33000	   51200	   14600000	  










1	   SF	   122000	   9040000	   298000	   1680000	   5700000	   323	   1960000	  
2	   SF	   320000	   7740000	   608000	   639000	   14300000	   2910	   3600000	  
3	   SF	   454000	   7640000	   202000	   382000	   10300000	   968	   1870000	  
4	   SF	   268000	   14400000	   375000	   266000	   5900000	   1290	   1940000	  
5	   SF	   77800	   4700000	   361000	   365000	   13100000	   1620	   2070000	  
6	   SF	   205000	   9060000	   838000	   2010000	   11100000	   1940	   4420000	  
7	   SF	   185000	   12200000	   949000	   3670000	   10800000	   3230	   6200000	  
1	   HM	   77500	   4110000	   94500	   42900000	   1480000	   1290	   1960000	  
2	   HM	   174000	   8370000	   164000	   9760000	   4430000	   1940	   2000000	  
3	   HM	   82600	   7180000	   205000	   15600000	   8480000	   2910	   4240000	  
4	   HM	   125000	   4140000	   162000	   13900000	   7330000	   2580	   3030000	  
5	   HM	   94300	   5720000	   221000	   32100000	   1900000	   2580	   7780000	  
6	   HM	   63900	   5230000	   208000	   16900000	   735000	   1940	   3660000	  
7	   HM	   415000	   5920000	   382000	   9140000	   3100000	   1940	   1430000	  
1	   CF	   152000	   11000000	   113000	   3430000	   2150000	   1290	   1120000	  
2	   CF	   125000	   7240000	   196000	   6180000	   5850000	   1620	   2040000	  
3	   CF	   42300	   341000	   129000	   112000	   2000000	   2580	   2150000	  
4	   CF	   98900	   3590000	   108000	   3980000	   2340000	   1940	   1590000	  
5	   CF	   144000	   7320000	   300000	   478000	   8760000	   2580	   1730000	  
6	   CF	   151000	   9790000	   204000	   996000	   10500000	   3230	   1620000	  




type	   Fumarate	   malate	   oxaloacetate	   PRPP	   xanthosine	   GDP	   GTP	  
1	   SF	   151000	   108000	   427000	   682000	   1990000	   30700	   31700	  
2	   SF	   406000	   249000	   1300000	   1410000	   3340000	   42300	   9210	  
3	   SF	   172000	   109000	   450000	   1000000	   2140000	   9370	   14900	  
4	   SF	   224000	   199000	   744000	   660000	   2300000	   10300	   13600	  
5	   SF	   233000	   117000	   619000	   1050000	   1780000	   18700	   9690	  
6	   SF	   421000	   520000	   1280000	   1000000	   3560000	   8720	   27800	  
7	   SF	   705000	   339000	   1480000	   1720000	   3070000	   24100	   37300	  
1	   HM	   304000	   200000	   465000	   1720000	   1350000	   18400	   19900	  
2	   HM	   690000	   580000	   846000	   425000	   4310000	   16200	   21300	  
3	   HM	   744000	   976000	   1260000	   1110000	   5120000	   31000	   14200	  
4	   HM	   767000	   1460000	   1400000	   1280000	   3530000	   37100	   17800	  
5	   HM	   1300000	   544000	   2000000	   1020000	   2990000	   31300	   11000	  
6	   HM	   536000	   424000	   825000	   1340000	   4660000	   28700	   16300	  
7	   HM	   1400000	   469000	   2270000	   36600	   11700000	   34900	   40100	  
1	   CF	   116000	   490000	   363000	   1230000	   1820000	   7100	   39100	  
2	   CF	   132000	   330000	   455000	   1140000	   2080000	   7750	   20000	  
3	   CF	   181000	   124000	   355000	   1610000	   1390000	   9040	   10700	  
4	   CF	   198000	   115000	   355000	   1140000	   1480000	   16200	   9370	  
5	   CF	   497000	   553000	   523000	   1280000	   2960000	   7750	   18100	  
6	   CF	   143000	   170000	   463000	   1590000	   1690000	   6780	   13200	  




type	   ADP	   ATP	   cAMP	   Allantoin	   GSHneg	   GSSGneg	   Lactate	  
1	   SF	   3550	   3870	   1480000	   348000	   1620	   0	   1080000	  
2	   SF	   7430	   2580	   2540000	   325000	   4520	   969	   1910000	  




4	   SF	   4200	   9370	   2410000	   896000	   9370	   646	   1520000	  
5	   SF	   9040	   17800	   1160000	   56000	   1290	   646	   1320000	  
6	   SF	   1940	   27800	   4100000	   1360000	   78200	   646	   2410000	  
7	   SF	   20400	   128000	   2550000	   375000	   47800	   1610	   1870000	  
1	   HM	   6620	   2260	   1160000	   1400000	   6780	   0	   5440000	  
2	   HM	   3070	   646	   3270000	   1770000	   12000	   0	   1740000	  
3	   HM	   3880	   1940	   3950000	   350000	   61700	   323	   2060000	  
4	   HM	   7430	   1610	   2970000	   330000	   2910	   323	   1780000	  
5	   HM	   8070	   2910	   2600000	   205000	   6780	   0	   2010000	  
6	   HM	   3550	   1620	   4020000	   1270000	   20400	   0	   1140000	  
7	   HM	   10700	   1620	   8250000	   258000	   11600	   646	   4780000	  
1	   CF	   3550	   646	   1110000	   1020000	   1940	   0	   947000	  
2	   CF	   2260	   1940	   2720000	   61900	   1610	   0	   1590000	  
3	   CF	   2910	   968	   2450000	   10300	   323	   0	   1080000	  
4	   CF	   3550	   1940	   1760000	   82000	   3880	   0	   1020000	  
5	   CF	   7430	   969	   2990000	   487000	   8070	   323	   1460000	  
6	   CF	   9370	   969	   1670000	   507000	   8080	   323	   950000	  












6-­‐P	   TPP	   FMN	   NADneg	  
1	   SF	   34600	   1500000	   103000000	   2260	   1610	   26800	   646	  
2	   SF	   32400	   3040000	   131000000	   1940	   1940	   85600	   1290	  
3	   SF	   71500	   2260000	   150000000	   1940	   1290	   13600	   646	  
4	   SF	   342000	   4310000	   120000000	   2580	   3880	   13200	   1940	  
5	   SF	   6780	   2290000	   99900000	   1940	   6780	   229000	   645	  
6	   SF	   16000	   6230000	   230000000	   2260	   1290	   17400	   323	  
7	   SF	   206000	   3780000	   141000000	   6140	   3550	   166000	   969	  
1	   HM	   50100	   2160000	   118000000	   1290	   27800	   13200	   646	  
2	   HM	   58100	   5170000	   139000000	   5490	   2910	   39100	   1610	  
3	   HM	   30700	   5420000	   221000000	   2100	   6140	   37500	   969	  
4	   HM	   28600	   3830000	   163000000	   5810	   2580	   24900	   646	  
5	   HM	   25800	   5220000	   228000000	   14200	   1610	   43300	   1620	  
6	   HM	   49100	   5630000	   105000000	   5810	   4200	   15200	   1290	  
7	   HM	   120000	   7780000	   176000000	   7110	   1940	   112000	   646	  
1	   CF	   29900	   1360000	   103000000	   1620	   2910	   8070	   1290	  
2	   CF	   83500	   2820000	   126000000	   4200	   2260	   29400	   2260	  
3	   CF	   6460	   2450000	   170000000	   1610	   1940	   25800	   1940	  
4	   CF	   36700	   2030000	   165000000	   1940	   2910	   19400	   645	  
5	   CF	   32600	   3960000	   68100000	   3870	   1620	   18700	   3230	  
6	   CF	   95000	   3030000	   110000000	   1290	   1620	   21000	   969	  




type	   NADHneg	   NADPneg	   NADPHneg	  
propCoAne





1	   SF	   968	   323	   2580	   1620	   646	   323	   6140	  
2	   SF	   969	   0	   1290	   1290	   1940	   323	   20400	  
3	   SF	   969	   0	   1940	   968	   1290	   323	   10000	  
4	   SF	   969	   323	   2580	   9040	   645	   323	   9370	  
5	   SF	   1290	   646	   1620	   1610	   968	   645	   2260	  




7	   SF	   4200	   1290	   7110	   24600	   26500	   1610	   4520	  
1	   HM	   3230	   0	   1940	   12000	   6460	   646	   9690	  
2	   HM	   1940	   323	   2580	   2910	   2580	   323	   19700	  
3	   HM	   968	   0	   969	   12400	   6140	   323	   10300	  
4	   HM	   4200	   0	   1290	   16500	   2580	   323	   6140	  
5	   HM	   969	   0	   969	   12900	   2910	   323	   18100	  
6	   HM	   645	   323	   2260	   3550	   2580	   645	   18400	  
7	   HM	   15200	   323	   2260	   52300	   37800	   323	   29100	  
1	   CF	   1940	   0	   2260	   646	   6130	   0	   13900	  
2	   CF	   968	   0	   2260	   323	   6140	   323	   14900	  
3	   CF	   969	   323	   1290	   968	   323	   0	   9370	  
4	   CF	   646	   0	   323	   4520	   3550	   323	   7430	  
5	   CF	   969	   323	   1610	   2260	   9040	   1290	   10300	  
6	   CF	   969	   0	   1610	   1940	   6140	   646	   12600	  






rylyCoA	   glycerate	   glyoxylate	   SAH_neg	  
Ascorbic	  
Acid	   	  	   	  	  
1	   SF	   969	   9320000	   108000	   4520	   3600000	   	  	   	  	  
2	   SF	   1290	   18800000	   138000	   3870	   4660000	   	  	   	  	  
3	   SF	   323	   17200000	   113000	   2910	   838000	   	  	   	  	  
4	   SF	   2580	   14900000	   165000	   9040	   11100000	   	  	   	  	  
5	   SF	   1620	   12800000	   9370	   2260	   704000	   	  	   	  	  
6	   SF	   5490	   7050000	   153000	   6460	   2850000	   	  	   	  	  
7	   SF	   37800	   2680000	   131000	   17400	   3360000	   	  	   	  	  
1	   HM	   4840	   13300000	   93700	   11600	   13700000	   	  	   	  	  
2	   HM	   1290	   10100000	   153000	   5170	   10300000	   	  	   	  	  
3	   HM	   1940	   3030000	   91400	   13600	   1420000	   	  	   	  	  
4	   HM	   1290	   2980000	   66900	   7110	   2850000	   	  	   	  	  
5	   HM	   1290	   1720000	   81400	   8400	   852000	   	  	   	  	  
6	   HM	   646	   4410000	   219000	   4840	   6340000	   	  	   	  	  
7	   HM	   14900	   2640000	   136000	   1940	   462000	   	  	   	  	  
1	   CF	   1940	   12600000	   94000	   5490	   4660000	   	  	   	  	  
2	   CF	   646	   8710000	   121000	   5170	   406000	   	  	   	  	  
3	   CF	   323	   6860000	   80600	   1610	   57200	   	  	   	  	  
4	   CF	   2260	   8090000	   48100	   6780	   336000	   	  	   	  	  
5	   CF	   323	   9930000	   156000	   5490	   8580000	   	  	   	  	  
6	   CF	   1620	   4740000	   79500	   2260	   5980000	   	  	   	  	  
7	   CF	   969	   8700000	   242000	   9370	   6360000	   	  	   	  	  
 
